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Background: Paraneoplastic neurological syndromes (PNS) are rare immune-
mediated diseases triggered by cancer, and characterized by circulating onconeural 
antibodies directed against antigens expressed by neurons and tumor cells. One of the 
most common forms of PNS is paraneoplastic cerebellar degeneration (PCD). In 
patients with PCD and ovarian or breast cancer, the dominant onconeural antibody is 
anti-Yo, detected in serum and cerebrospinal fluid (CSF). Anti-Yo targets two 
intracellular antigens, cerebellar degeneration-related protein 2 (CDR2) and CDR2-
like (CDR2L), expressed in the nucleus and cytoplasm of Purkinje neurons in the 
cerebellum, respectively. The interaction between anti-Yo and CDR proteins is thought 
to mediate Purkinje neuron dysfunction and death, leaving the patients in a severely 
disabled state. 
The pathomechanisms underlying PCD, including the cellular functions and molecular 
mechanisms driven by the CDR proteins, are limited. About ten years ago, CDR2L was 
identified as a new target associated with PCD, and its specific location and neuronal 
functions remains elusive. Herein, we aim to draw a clearer picture of the anti-Yo 
associated neurodegeneration by addressing which onconeural antigen is the major 
target of Yo antibodies, identifying the subcellular localization of CDR2 and CDR2L 
and interaction partners. Finally, we evaluate the possibility of including CDR2L as a 
diagnostic marker when diagnosing patients with PCD.    
Aims: The overarching aim of this work was to gain in depth knowledge about CDR2 
and CDR2L in anti-Yo associated PCD.  
Materials and methods: In paper I, anti-Yo reactivity towards CDR2 and CDR2L was 
addressed by staining cerebellar sections and cancer cells, and performing 
immunoprecipitation and fluorescent immunoblotting analysis. HepG2 cells were 
transfected to investigate whether Yo antibodies detect recombinant forms of the 
proteins. In paper II, mass spectrometry based proteomics was used to determine 
antibody specificity, and to identify CDR2 and CDR2L protein binding partners. 
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Findings were further investigated by co-immunoprecipitation, proximity ligation 
assay and co-localization studies using super-resolution microscopy. 
Immunochemistry and super-resolution microscopy enabled determination of the 
subcellular localizations of CDR2 and CDR2L. In paper III, the potential of including 
CDR2L as a diagnostic marker in PCD was assessed by developing two in-house 
techniques, cell-based assay for CDR2L and western blot analysis of recombinant 
CDR2 and CDR2L.  
Results: We show that CDR2L is the major Yo antigen and that including CDR2L as 
a marker in the diagnosis of PCD greatly improves test specificity. Furthermore, the 
subcellular location of CDR2L is found to be in the cell cytoplasm, more specifically 
in direct contact with the ribosomal subunit protein, rpS6. CDR2 localizes to the 
nucleus in contact with nuclear speckle proteins, SON and eIF4A3.     
Conclusions: Identifying CDR2L as the major Yo antigen is an important finding in 
the work of increasing test specificity for PCD diagnosis, and is essential for further 
investigation of PCD pathogenesis. However, a central role of CDR2 in PCD can not 
be excluded. By determining the subcellular locations of the proteins and binding 
partners, we are one step closer in understanding the functions of CDR2 and CDR2L 




1.1 The nervous system  
The nervous system is a complex network of neurons that transmit signals between 
different parts of the body and coordinate the body’s functions. The nervous system 
has two structural components, the peripheral nervous system and the central nervous 
system (CNS).  
1.1.1 The peripheral nervous system  
The peripheral nervous system consists of nerves that branches from the brain and 
spinal cord (the central nervous system), and has two functional subdivisions, a sensory 
component and a motor component. The sensory component includes sensory 
(afferent) neurons that link receptors on the body’s surface or within tissues to the CNS. 
The motor component of the peripheral nervous system can be divided into the somatic 
and autonomic motor divisions. The somatic motor system involves voluntary 
movements driven by motor (efferent) neurons that connect the CNS to skeletal 
muscles. The autonomic motor system includes cells that innervate involuntary 
structures, such as smooth muscles, cardiac muscles and glands within the body.1        
1.1.2 The central nervous system  
The CNS comprises the spinal cord and the brain. The brain is divided into three major 
structures: the forebrain, the midbrain and the hindbrain.1 The forebrain includes 
thalamus, hypothalamus, and cerebrum, which encompasses the cerebral cortex and 
subcortical structures, such as the hippocampus, amygdala, and basal ganglia. The 
thalamus and hypothalamus are in charge of homeostasis (e.g. respiration, blood 
pressure, body temperature) and relay information to the cerebral cortex from other 
brain regions. The cerebral cortex is important for conscious thought, perception, and 
learning. It comprises a six-layered structure, referred to as neocortex, each layer with 
its own composition of neuronal cells. The hippocampus is important for memory 
formation, the amygdala processes emotional information, and the basal ganglia are a 
group of subcortical nuclei responsible for motor control.2 The midbrain connects the 
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forebrain to the hindbrain. The midbrain and the hindbrain compose the brainstem. The 
hindbrain involves the medulla, pons and cerebellum, each with its own unique 
structure and function. Together they maintain balance, posture, coordinate movement, 
relay sensory information and assist in autonomic functions, such as breathing, heart 
rate and blood pressure.3 The cerebellum is essential for coordination and planning of 
movements, and will be addressed in the following. 
Cerebellum 
The human cerebellum has mainly been recognized as the regulator of highly skilled 
movements, especially the planning and execution of complex spatial and temporal 
sequences of movement. In the last ten years there has been an increasing focus on 
studying the role of the cerebellum in cognition, thus challenging the view that the 
cerebellum soley contributes to planning and execution of movements.4-6   
The cerebellum contains three cortical layers: the molecular layer, the Purkinje neuron 
layer and the granular layer (Fig 1.1.2).7 The innermost cortical layer is the granular 
layer, containing mossy fibers, the cell bodies of granule cells, and Golgi cells. The 
middle cerebellar layer is the Purkinje layer, containing the cell bodies of Purkinje 
neurons and Bergmann glial cells. The outermost cortical layer is the molecular layer, 
containing the dendrites of Purkinje neurons and the inhibitory stellate and basket 
cells.7  
Mossy fibers are axons that originate from multiple brainstem nuclei and synapse on 
neurons in the deep cerebellar nuclei and on granule cells. The granule cells constitute 
the majority of neurons in the brain and give rise to axons called parallel fibers that 
ascend to the molecular layer of the cerebellar cortex and synapse onto Purkinje neuron 
dendrites8. Parallel fibers activate stellate and basket cells, which provide an inhibitory 
input to Purkinje neuron dendrites. Purkinje neurons are also innervated by climbing 
fibers, which arise from the inferior olivary nucleus in the medulla oblongata. The 
convergence of parallel fibers and climbing fibers to Purkinje neurons has been 
proposed to be important for cerebellar learning.9 Purkinje neuron axons project into 
the deep cerebellar nuclei, where they exert inhibitory effects via release of the 
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inhibitory neurotransmitter, gamma-aminobutyric acid (GABA). Purkinje neurons 
constitute the sole output of the cerebellar cortex, which is wholly inhibitory.8 Neurons 
in the deep cerebellar nuclei receive excitatory input from mossy and climbing fibers. 
An interplay between these inhibitory and excitatory projections serve to shape the 
discharge patterns to the thalamus.10   
 
Figure 1.1.2: Neural circuit of the cerebellum. Reprinted with permission from Springer Nature, License 
#5031381453503: Nature reviews neuroscience, Anatomical and physiological foundations of cerebellar 
information processing, Apps et al. 2005.11 
1.2 Neurons and glial cells  
Cells of the nervous system can be divided into two main categories: neurons and glial 
cells. The glia to neuron ratio varies across the different human brain structures, with 
an almost equal amount in the cerebral cortex, six times as many glial cells in the spinal 
cord and around 20 times as many neurons in the cerebellum.12      
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1.2.1 Neurons 
Neurons have diverse molecular, morphological and functional properties, but they all 
contain four distinct regions: the dendrites, the cell body, the axon and axon terminals.13 
Interneuronal communication is required for normal brain function and relies on two 
types of signaling mechanisms – action potentials and synaptic transmissions. Action 
potentials are electrical signals conducted from the cell body towards the axon 
terminals. Action potentials can trigger two main modalities of synaptic transmission, 
chemical and electrical.14 At chemical synapses, information is conveyed via the 
release of neurotransmitters from presynaptic neurons to postsynaptic neurons via 
functional junctions (synapses). Chemical synapses can be of excitatory (e.g. 
glutamate) or inhibitory (e.g. GABA) nature depending on the released 
neurotransmitter, and can undergo response-dependent modifications to alter their 
activity pattern, referred to as synaptic plasticity. At electrical synapses there is a direct 
connection between the cytoplasm of a presynaptic and postsynaptic neuron via 
intracellular channels called gap junctions.14  
Purkinje neurons  
Purkinje neurons are characterized by their unique fan-shaped structure (Fig 1.2.1). 
The soma of Purkinje neurons are located in a single-layer manner, making up the 
Purkinje neuron layer of the cerebellum. One or two primary dendrites extend from the 
soma to form highly branched, non-overlapping dendrites which aborize into the 
molecular layer. Parallel fibers pass perpendicularly through Purkinje neuron dendrites 
in a grid-like structure, making up approximately 100,000 synaptic connections. The 
Purkinje neuron axon extends through the granular layer to the deep cerebellar nuclei.15  
Purkinje neurons represent the sole output of the cerebellar cortex.16 It follows that 
disturbances of Purkinje neuron signalling will cause severe symptoms. These include 
reduced coordination and fine movement (cerebellar ataxia), involuntary eye 
movement (nystagmus), and dysfunction of articulation (dysarthria).17 Purkinje 
neurons are prone to damage caused by toxins (ethanol), autoimmune diseases (gluten 
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ataxia), genetic mutations (spinocerebellar ataxia) and neurodegenerative diseases 
(multiple system atrophy).16   
Figure 1.2.1: Purkinje neuron with its unique fan-shaped structure and extensive dendritic branches. Reprinted 
with permission from Springer Nature, License #5031380743925: Springer Nature, Dendritic Self-Avoidance 
and Morphological Development of Cerebellar Purkinje Cells, Fujishima et al. 2018.15 
1.2.2 Glial cells 
Glial cells are non-neuronal, supportive cells of the nervous system. They are involved 
in homeostasis (synaptic action, neurotransmitter uptake, maintaining the ionic and 
water milieu), aiding in defence, and repair of injured nerves.18 There are two classes 
of glial cells in the mature CNS: macroglia (astrocytes and oligodendrocytes) and 
microglia. Astrocytes function in appropriate maintenance of chemical environments 
for neuronal signaling and blood-brain barrier (BBB) maintenance. Oligodendrocytes 
are myelin-producing cells that insulate axons, thereby increasing the transmission of 
action potentials.19 Microglia are the resident immune cells of the CNS, with three 
essential functions: 1) sensing environmental changes, 2) physiologic housekeeping, 
and 3) defence against modified or harmful non-self antigens.20  
1.3 The immune system of the central nervous system  
The blood-brain barrier  
The BBB is a semipermeable border that regulates the entry of immune cells into the 
CNS, and strictly controls the exchange of substances between the CNS and the blood 
(Fig 1.3).21 This tight barrier consists of endothelial cells that express tight junction 
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proteins and restricts the passage of solutes. Neurons and astrocytes also reside in close 
proximity to the BBB. This allows for neurons to respond to changes in the local milieu, 
whereas astrocytes help regulate ion and water flux.22 Thus, the BBB provides 
anatomical and physical protection for the CNS, which is of particular importance since 
BBB dysfunction plays a key role in neurodegenerative disorders by affecting 
movement of immune cells and immune mediators into the brain.23        
 
Figure 1.3: Immune system in the central nervous system during homeostasis in a non diseased brain. Reprinted 
with permission from Springer Nature, License #5031890971092: Nature neuroscience, The role of peripheral 
immune cells in the CNS in steady state and disease, Prinz and Priller 2017.24 
The meninges  
The meninges are composed of three protective tissue layers: the dura mater, the 
arachnoid mater and the pia mater, which surround and support the brain and spinal 
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cord. The subarachnoid space exist between the arachnoid mater and pia mater, and 
consist of CSF, major blood vessels and cisterns (enlarged pockets of CSF).25  
The ventricular system  
The ventricular system is responsible for the production, transport and reabsorption of 
CSF. It is composed of a communicating network of cavities located in the core of the 
forebrain and brainstem, the ventricles. The choroid plexus is a vascular structure 
present in all four ventricles that produce CSF.25 
The blood-cerebrospinal fluid barrier 
Choroid plexus epithelial cells and tight junctions establish the blood-CSF barrier and 
regulate the passage of solutes from blood into CSF.26 The blood-CSF barrier has also 
been shown to regulate the entry of leukocytes to the CNS.27 
The glymphatic system 
Interstitial fluid, fluid between blood vessels and cells, and CSF drain to lymph nodes 
by separate ways, but an exchange system between the two has been identified, called 
the glymphatic system. This system provides efficient elimination of soluble proteins 
and metabolites from the CNS, essential for maintaining brain homeostasis.28 
1.4 The immune system  
Immunity is derived from the Latin word immunitas, and refers to protection from 
infectious disease. The cells and molecules responsible for immunity constitute the 
immune system.29 The skin, respiratory or intestinal tract, and other areas are protected 
against microbes, viruses, cancer cells and toxins, by the immune systems two 
fundamental lines of defense: innate immunity and adaptive immunity.30                                                          
1.4.1 Innate immunity  
Innate immunity provides the initial defence against infections and consists of four 
types of barriers: anatomic, physiologic, phagocytic and inflammatory. The anatomic 
barrier comprises intact epithelial surfaces that forms physical barriers between 
microbes in the external environment and host tissue. The physiological barrier refers 
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to changes in body temperature to inhibit growth of some pathogens, acidic pH in the 
stomach to kill undigested microbes or chemical mediators, such as lysozyme 
digestion. Cells with specialized phagocytic functions, primarily neutrophils and 
macrophages, ingest and sometimes digest whole organisms or foreign particles, which 
are important functions in innate immunity. Finally, blood and extracellular fluids 
contain molecules that recognize microbes and promote host defense, including 
recruitment of immune cells. This inflammatory barrier is sometimes called the 
humoral branch of innate immunity, and can be compared to the humoral branch of 
adaptive immunity.30 Innate immune responses do not require prior exposure to 
microbes and there is no prominent change in the magnitude upon repeated exposure, 
which contrasts adaptive immunity.  
This first line of host defense highly depends on pattern recognition receptors (PRRs) 
recognizing unique microbial molecules, called pathogen-associated molecular 
patterns (PAMPs). Different microbes produce varying PAMPs, such as cell-wall 
components, lipopolysaccharides, on gram-negative bacteria.30 Upon PAMP-PRR 
interactions, intracellular signaling cascades are triggered, resulting in expression of 
various inflammatory molecules, such as cytokines and chemokines.31 Cytokines 
orchestra proinflammatory or anti-inflammatory host responses depending on the 
nature of the target cell and nature of the activating signal.32 Tumor necrosis factor 
(TNF), interleukin 1 (IL-1) and interleukin 6 (IL-6) are among the key inflammatory 
cytokines. These cytokines are involved in local inflammation and recruitment of 
phagocytic cells and antigen-presenting cells. Dendritic cells are conventional antigen-
presenting cells that express a group of proteins called major histocompatibility 
complex (MHC). After digesting an antigen into peptides, dendritic cells, present these 
MHC bound peptides to T cells. Thus, antigen-presenting cells play an important role 
in the crosstalk between innate and adaptive immunity.   
1.4.2 Adaptive immunity  
Adaptive immunity is critical when innate immunity fails to eliminate the infectious 
agents. The main characteristics of adaptive immunity is the ability to distinguish 
between different self and non-self substances (antigens), its specificity, and its ability 
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to respond more vigorously upon subsequent infection, its memory.33 There are two 
broad classes of adaptive immunity: cell-mediated immunity and humoral immunity.  
Cell-mediated immunity  
Cell-mediated immunity is mediated by T cells that derive from hematopoietic stem 
cells in the bone marrow and mature in the thymus.30 T cells recognize intracellular 
microbes that are inaccessible to circulating antibodies, and promote destruction of the 
microbes or infected cells.29 Fragments of the microbes are displayed on MHC 
molecules by antigen-presenting cells. This MHC/antigen complex is recognized by 
unique antigen-binding receptors, T cell receptors (TCR), together with co-stimulatory 
receptors, cluster of differentiation (CD). This interaction leads to T cell activation, 
proliferation, differentiation and cytokine release.34  
T cells can differentiate into functionally different populations, such as T helper (Th) 
cells (CD4+ cells), cytotoxic T cells (CD8+ cells) and regulatory T cells, depending on 
the interaction between TCRs with peptides presented by class I or class II MHC 
molecules.30 CD8+ cytotoxic T cells are activated by the interaction with peptides 
bound to MHC class I molecules, whereas CD4+ Th cells are activated by the 
interaction to peptides on MHC class II molecules. Upon activation, CD8+ cytotoxic T 
cells eliminate reservoirs of infection by destructing cells infected by viruses or 
bacteria. Unlike CD8+ cytotoxic T cells, CD4+ Th cells have no cytotoxic or phagocytic 
activity and cannot directly kill infected cells. Instead, CD4+ Th cells secrete cytokines 
that recruit other cells to aid in these tasks, such as helping phagocytes to kill infectious 
pathogens. Regulatory T cells, a subset of CD4+ T cells, function mainly to suppress 
immune responses and prevent responses to self-antigens. CD4+ T cells activate both 
cellular and humoral immune responses.30, 33 
Humoral immunity 
B cells are derived from hematopoietic stem cells in the bone marrow. This is also 
where they mature and assemble their antigen receptors, surface immunoglobulin 
(Ig).33 Ig molecules are composed of two identical 50 kDa heavy chains and two 
identical 25 kDa light chains connected by disulfide bonds. Both the heavy and light 
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chains consist of amino terminal portions that vary in amino acid sequence between 
antibody molecules, and that participate in antigen recognition.33 Ig, also known as 
antibodies, are synthesized by B cells in two forms: membrane bound antibodies on the 
surface of B cells, or secreted antibodies that neutralize toxins and target them for 
phagocytosis.29 Upon activation, B cells proliferate and differentiate into antibody 
secreting plasma cells. These cells produce large amounts of antibodies, are short lived 
and often undergo apoptosis after the immune response is eliminated. B cells can also 
differentiate into memory B cells that respond faster and more effectively upon re-
exposure.29, 30   
The complement system is an important effector mechanism of both innate and 
adaptive immunity. It is composed of over 25 plasma and cell surface proteins that 
interact with one another and with other molecules of the immune system to eliminate 
microbes. Three major pathways ensure complement activation: alternative, classical 
and lectin pathways. The alternative pathway is activated by complement protein C3 
binding to microbial surfaces, the classical pathway by C1 binding to antigen-antibody 
complexes and the lectin pathway by binding of microbial polysaccharides to mannose-
binding lectin, ficolins or collectins. Only the classical pathway relies on antibody 
binding for activation. Despite which pathways are generated, the final steps and the 
complement activated are the same. The proteolysis of C3 results in activation of C5 
convertase, which cleaves C5 to C5a and C5b. Generation of the C5a fragment is 
important in the formation of membrane pore complexes in cell membranes of 
microbial targets, which kills the targets by osmotic lysis.33 
1.4.3 Antibodies and antigens 
As noted, antibodies consist of two heavy and two light chains bound by disulfide 
bonds (Fig 1.4.3). The antigen-antibody binding site consists of two variable (V) 
domains, the light chain, VL, and the heavy chain, VH. These domains contain three 
sub-regions that are highly variable among different antibodies, known as 
hypervariable regions. Furthermore, the variable regions form the fragment antigen-
binding (Fab) region through its non-covalent interaction with the constant CL and CH1 
domains. The Fab region mediates specific recognition of antigens.35  
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Figure 1.4.3: Structure of an antibody. The Y shaped antibody consists of two heavy and two light chains 
connected via disulfide bonds. V, variable; C, constant; Fab, antigen-binding fragment; Fc, crystallization 
fragment. Reprinted with permission from John Wiley and Sons, License #5044400418103. John Wiley and 
Sons, Roitt's Essential Immunology, 12th Edition, Burton et al. 2011.36 
The heavy chain constant regions can self-associate and crystallize to form the 
crystallization fragment (Fc) region. This region is distant from the antigen-antibody 
site and interacts directly with other elements of the immune system, including binding 
to Fc receptors (FcRs) and activating the complement system.30, 37  
Antibody molecules are divided into different classes (isotypes), IgA, IgD, IgE, IgG, 
and IgM, depending on the structure of their heavy chain constant region. These classes 
have different biological functions, mainly mediated by binding of the constant regions 
of the heavy chain to FcRs.37   
FcRs are membrane molecules expressed by several cells, among others, B cells, 
macrophages and neutrophils, that aid in the recognition of the Fc region of several Ig 
classes and subclasses. These receptors constitute critical elements for activating or 
down-modulating immune responses and combine humoral and cell-mediated 
immunity. Thus, impared regulation by FcRs can lead to hyperreactivity to foreign or 
self-antigens.38   
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Antibodies have many practical applications in medical diagnosis, therapy and 
research. A key to understanding the various functions of antibodies in numerous 
applications is to determine the epitopes (binding sites) they recognize. Two classes of 
epitopes exist: linear epitopes, in which a stretch of continuous amino acids are 
sufficient for binding, and conformational epitopes, where protein folding enables 
amino acid residues to form an antigenic surface that can be bound by the antibody. 
Binding of an epitope to its antibody depends on the spatial arrangement of the epitope 
and non-covalent, reversible binding between the antigen and antibody. The strength 
of the interaction between one epitope and one antibody reflects the affinity of the 
antibody, whereas the strength of the antibody binding to all available epitopes on an 
antigen refers to its avidity.39, 40 Antibodies can cross-react with similar epitopes on 
other antigens, but most often with lower affinity. The ability the antibody has to 
recognize a specific epitope in the presence of other epitopes, reflects the antibody`s 
specificity.39  
Monoclonal and polyclonal antibodies can be purchased from commercial companies 
for research purposes. Monoclonal antibodies have often been preferred due to their 
homogeneity and consistency, making them suitable when studying changes in protein-
interactions or conformational changes. The drawback concerning the use of 
monoclonal antibodies is that small structural changes in the epitope or conformational 
changes, due to altered pH, salt concentration or post-translational modification, can 
markedly affect the function of the antibody. Polyclonal antibodies, on the other hand, 
are less prone to such variations in the cellular surroundings, due to its heterogeneity 
and ability to recognize numerous antigenic epitopes.39 Thus, the choice of antibody 
will greatly depend on the application.   
1.4.4 Autoimmunity  
One of the remarkable features of the immune system is its ability to react against 
foreign antigens while not reacting harmfully towards self-antigens. Such immune 
tolerance is regulated at the stage of immature B cell development by clonal deletion. 
Clonal deletion involves apoptosis of B cells that express receptors against self-
antigens before they mature into immunocompetent cells, thereby maintaining self-
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tolerance.41 In the thymus, T cells with potential reactivity against self-antigens are 
deleted through negative selection.42 Abnormalities in the regulation of these 
mechanisms may result in autoimmunity, the failure to maintain self-tolerance.29  
Effector mechanisms, such as circulating autoantibodies, autoreactive T cells and 
formation of immune complexes, contribute to various autoimmune diseases.29 
Autoantibodies are antibodies that react against self-antigens and that can be 
pathogenic.43 Serum or cerebrospinal fluid (CSF) autoantibodies have become a potent 
diagnostic marker for autoimmune diseases.44 Paraneoplastic cerebellar degeneration, 
described in chapter 1.5.2, are rare immune-mediated syndromes associated with the 
production of autoantibodies and antigen-specific T cells.  
1.4.5 Neuroinflammation  
Neuroinflammation is defined as inflammatory responses within the brain and spinal 
cord, triggered by aging, neurodegenerative diseases, injury or infection, and mediated 
by cytokines and chemokines.45, 46 Cytokines and chemokines regulate inflammatory 
responses throughout the body and are crucial for the brain’s immune function by 
acting as neuromodulators in neurodevelopment, neuroinflammation and synaptic 
transmission.46 Upon pathological states within the nervous system, microglia are 
activated. This leads to the production and release of proinflammatory cytokines and 
chemokines that trigger astrocytes and infiltration of peripheral immune cells to 
respond to the pathologic state. In general, this activation aids in protecting and 
repairing the CNS.45 Nonetheless, prolonged inflammation, chronic microglia 
activation and continual recruitment of effector cells can ultimately result in nerve 
injury and a well-balanced interplay between proinflammatory factors and repair is 
essentially defining the outcome of the neuroinflammatory process.45, 46   
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1.5 Paraneoplastic neurological syndromes 
Paraneoplastic neurological syndromes (PNS) are rare immune-mediated disorders that 
affect the nervous system in patients with cancer.47 These disorders are not caused by 
the direct tumor invasion, metastasis or consequence of treatment, but as a result of the 
immune response against neuronal proteins expressed by the tumor.48, 49 Essentially 
any region of the nervous system can be affected by PNS, ranging from involving 
single cell types (e.g. Purkinje neurons in the cerebellum) to multiple levels of the 
nervous system (e.g. encephalomyelitis).47, 48 Although all parts of the nervous system 
can be affected, eight syndromes have been classified as “classical” PNS: 
encephalomyelitis, limbic encephalitis, paraneoplastic cerebellar degeneration, 
opsoclonus–myoclonus, sensory neuronopathy, chronic gastrointestinal pseudo 
obstruction, Lambert–Eaton myasthenic syndrome, and dermatomyositis.50  
Pathophysiology 
PNS are mainly autoimmune but the roles of humoral and cellular mediated immunity 
remain unresolved, largely due to the complicated features of the different 
syndromes.47 A model has been proposed  (Fig 1.5), in which immature dendritic cells 
phagocytose apoptotic tumor cells, mature, and migrate to lymph nodes, whereby they 
activate CD4+ and CD8+ T cells, and B cells.47, 51 Activated tumor-specific T cells can 
trigger a feedback loop by inducing apoptosis and thereby amplifying the antitumor 
immune response, or cross the BBB and become an effector in specific brain regions 
depending on the nature of the PNS.47, 52 A humoral mediated response has been 
proposed due to the detection of a greater portion of IgG in CSF compared to the serum, 
thus indicating that the antibody is being selectively transported across the BBB or is 
produced by the CNS and projected into the CSF.53 Most probably, clones of B cells 
cross the BBB to produce elevated titers of the specific antibody in the CNS.53 In other 
instances of PNS, antibodies in association with a CD8+ T cell response is likely the 







Figure 1.5: Proposed model for pathogenesis of paraneoplastic neurological syndromes. Dendritic cells 
phagocytose tumor cells, migrate to lymph nodes and present tumor antigens to CD4+ and CD8+ T cells and B 
cells. CD8+ T cells mature into cytotoxic T cells that can attack tumor cells, or neurons expressing antigens they 
share with the tumor. B cells mature into antibody-secreting plasma cells that can react against the tumor, portions 
outside the nervous system, such as the neuromuscular junction or in some instances attack neurons directly. 
Reproduced with permission from Darnell and Posner 2003,47 Copyright Massachusetts Medical Society.  
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Antibodies as biomarkers of PNS 
Paraneoplastic autoimmunity can be directed against intracellular antigens or cell-
surface antigens.55 Paraneoplastic antibodies, also called onconeural antibodies, that 
target intracellular antigens may not have a direct pathogenic effect, as antigen-specific 
CD8+ T cells probably exert a cytotoxic effect causing neuronal death.55 These 
onconeural antibodies almost always indicate the presence of an underlying cancer. 
Thus, even though these antibodies may not be pathogenic in nature, they serve as 
excellent biomarkers for PNS.56 Some of the most well characterized onconeural 
antibodies include, Hu, Yo, Ri, collapsin response mediator protein 5 (CRMP5) and 
Ma1/Ma2 (Table 1.5).56 Hu antibodies, which target all neurons, are associated with 
widespread PNS such as encephalomyelitis and sensory neuropathy. Yo antibodies, on 
the other hand, mainly target Purkinje neurons and are associated with a limited PNS 
called paraneoplastic cerebellar degeneration.57 PNS associated with antibodies 
directed against intracellular antigens are characterized by poor response to treatment 
and relentless progression due to the rapid neuronal loss.55  
Autoantibodies targeting cell-surface antigens can occur in patients with or without 
cancer. The frequency and type of cancer can vary according to the autoantibody, with 
over 50% of patients with anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid receptor (AMPAR) and anti-GABAB receptor having underlying malignant 
tumors, and less than 5% of patients with anti-leucine-rich, glioma inactivated 1 (LGI1) 
having a underlying, often non-malignant, tumor.55, 56 Antibodies that target cell-
surface antigens are considered to have a direct pathogenic effect, but this is reversible 
in many instances. Thus, PNS associated with these autoantibodies are more likely to 
respond to immunotherapy.47, 54, 55, 58, 59 
Antibodies associated with PNS detected in patient sera or CSF are extremely useful 
diagnostic biomarkers.60 Identification of onconeural antibodies with intracellular 
antigens reliably predicts that the PNS is paraneoplastic, and guides the search for an 
underlying tumor.56 Several screening tests have been developed, including indirect 
immunofluorescence (IIF) of rat brain sections, western blot analysis, cell-based assays 
(CBAs) and commercial line immunoassays.44 Especially commercially available line 
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immunoassays provide rapid and easy detection of several antibodies simultaneously, 
but the diagnostic value has been questioned due limited information regarding test 
reliability, sensitivity and specificity.61       
Table 1.5: PNS autoantibodies, their antigens and associated tumors.  
Antibody  Antigen PNS Associated tumor 
Antibodies targeting intracellular antigens 
Yo CDR2L/CDR2 PCD Ovarian, breast and fallopian 
tube 
Hu HuD Encephalomyelitis, sensory 
neuronopathy 
SCLC, NSCLC and 
extrathoracic cancers 
Ri NOVA1/NOVA2 Brainstem encephalitis, opsoclonus Breast, lung and other cancers 
SOX1 SOX1 LEMS, PCD SCLC, NSCLC and 
extrathoracic cancers 
Amphiphysin Amphiphysin SPS, encephalomyelitis, 
sensorimotor neuropathy 
SCLC, breast and other 
cancers 
MAP1B MAP1B Encephalomyelitis and/or 
sensorimotor neuropathy 
SCLC, NSCLC, and 
extrathoracic cancers 
CRMP5 CRMP5 Encephalomyelitis, sensorimotor 
neuropathy 
SCLC, NSCLC, thymoma and 
extra-thoracic cancers 
Ma1/Ma2 Ma1/Ma2 Limbic encephalitis and brainstem 
encephalitis 
Testicular, lung and other 
cancers 
Tr DNER PCD Hodkin lymphoma 
Antibodies targeting cell-surface antigens 
AMPAR GluA1/GluA2 Limbic encephalitis and non-focal 
encephalitis 
Lung, thymus, breast and other 
cancers 
GABABR B1 (GABABR 
subunit) 
Limbic encephalitis, cerebellar 
ataxia, opsoclonus myoclonus 
syndrome 
SCLC 
NMDAR GluN1 Encephalitis Teratoma 
mGlur5 mGlur5 Non-focal encephalitis Hodgkin lymphoma 
VGCC P/Q P/Q-type VGCC LEMS, PCD SCLC 
LGl1  Limbic encephalitis Thymoma 
AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; CDR2, cerebellar degeneration- 
related protein 2; CDR2L, CDR2-like; CRMP5, collapsin response mediator protein 5; DNER, delta and notch-
like epidermal growth factor-related receptor; GABABR, gamma-aminobutyric acid type B receptor; GluA1, 
glutamate receptor 1; GluA2, glutamate receptor 2; GluN1, NMDAR subunit NR1; HuD, Hu-antigen D; LEMS, 
Lambert-Eaton myasthenic syndrome; LGl1, leucine-rich, glioma inactivated 1; MAP1B, microtubule-associated 
protein 1B; mGlur5, metabotropic glutamate receptor 5; NMDAR, N-methyl-D-aspartate receptor; NOVA, 
neuro-oncological ventral antigen; NSCLC, non-small-cell lung carcinoma; PCD, paraneoplastic cerebellar 
degeneration; SCLC, small-cell lung carcinoma; SOX1, SRY-related high mobility group box 1; SPS, stiff-
person syndrome; VGCC P/Q, P/Q-type voltage-gated calcium channel. Reprinted by permission from Springer 
Nature, License #5031901477248: Nature reviews clinical oncology, Paraneoplastic neurological syndromes in 
the era of immune-checkpoint inhibitors, Graus et al. 2019.56  
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Clinical features and diagnosis 
The diagnosis of PNS is based on the type of syndrome (classic or non-classic), 
presence of onconeural antibodies, clinical symptoms and potential underlying 
cancer.56 A definite diagnosis of PNS can be made if: 1) a neurological syndrome 
appears with the detection of well characterized onconeural antibodies (such as anti-
Hu or anti-Yo), 2) a classical syndrome and a tumor is identified, regardless of the 
presence or absence of a onconeural antibody, 3) a non-classical syndrome that resolves 
or greatly improves after cancer treatment without simultaneous immunotherapy, or 4) 
a none-classical syndrome with onconeural antibodies and cancer develops within five 
years of diagnosing the neurological disorder.17 The clinical symptoms of PNS are 
diverse, but some features are common.47 In two-thirds of the cases, the diagnosis of 
PNS precedes the diagnosis of the cancer.62, 63 Detection of one or more paraneoplastic 
antibodies in serum or CSF prompts targeted tumor screening, since such antibodies 
often are associated with certain cancer types.55  
Treatment  
The two main treatment strategies involve immunotherapy and tumor treatment to 
remove the source of the antigenic stimulation. A combination approach might be 
favorable to improve the neurological outcome.47, 55 The most commonly used 
immunotherapies include corticosteroids, plasma exchange, intravenous 
immunoglobulins and rituximab.54 The response to treatment varies largely; PNS 
associated with antibodies to cell-surface antigens showing a greater response 
compared to PNS associated with antibodies to intracellular antigens.54 
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target cytotoxic 
T-lymphocyte antigen (CTLA4), programmed cell death 1 (PD-1) protein or PD-1 
ligand and promotes T cell activation and initiate tumor cell elimination.64 The 
introduction of ICIs has revolutionized the treatment across a wide range of 
malignancies, resulted in unprecedented survival rates and durable responses.65 
However, due to its generalized immune activation and lack of specificity, ICIs are 
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associated with a high risk of immune-related adverse effects, some of which can 
manifest as PNS.56, 66        
1.5.2 Paraneoplastic cerebellar degeneration 
Paraneoplastic cerebellar degeneration (PCD) is one of the most frequently detected 
PNS, characterized by rapidly progressing ataxia, nystagmus and dysarthria. PCD is 
associated with numerous different onconceural antibodies, the most well characterized 
being anti-Yo, anti-Hu, anti-Ri and anti-Tr. The tumors most commonly associated 
with these antibodies are SCLC (anti-Hu), gynecological and breast cancer (anti-Yo 
and anti-Ri), and Hodgkin's lymphoma (anti-Tr).67 Patients with PCD experience 
progressive symptoms from weeks to months, and due to the irreversible damage to the 
cerebellum, most patients are significantly disabled within the time the symptoms 
stabilize (within 6 months).67 There are no preventative measures and prognosis is 
poor.67       
Anti-Yo associated paraneoplastic cerebellar degeneration  
Anti-Yo was identified as an immunological marker for PCD by Greenlee and Brashear 
in 1983.57 Sera from two patients with ovarian cancer and PCD was used to stain human 
cerebellum sections. The sera contained an antibody termed anti-Yo, which produced 
cytoplasmic staining of Purkinje neurons and neurons within deep cerebellar nuclei.57 
Yo antibodies could also be detected in CSF, and often in higher titers compared to 
sera.53, 68 Immunostaining of post-mortem cerebellar sections from the patients 
identified a complete loss of Purkinje neurons, and a thinning of the granular cell layer 
(loss of granule cells), a characteristic feature of patients diagnosed with anti-Yo 
associated PCD.57, 62, 69   
Cerebellar degeneration related-proteins  
Extensive work in the late 1980`s and beginning of the 1990`s led to the identification 
of two anti-Yo target proteins: cerebellar degeneration-related protein 1 (CDR1) and 
cerebellar degeneration-related protein 2 (CDR2).70-74 In 1996, a third protein was 
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identified, first termed cerebellar degeneration-related protein 3, now referred to as 
CDR2-like (CDR2L), due to its 45% sequence identity  with CDR2.75, 76  
CDR1 is a 34 kDa protein, consisting of 34 inexact repetitive hexapeptides that account 
for approximately 50% of the amino acid sequence.72, 77 Although CDR1 is expressed 
in the cytosol and dendrites of Purkinje neurons, and in ovarian and breast cancer tissue, 
no clear association with PCD has been identified.77 Thus, CDR1 will not be addressed 
in further detail, as it is beyond the scope of this work.   
The biological functions of CDR2 is partly characterized through the identification of 
a leucine zipper motif in its amino acid sequence,71, 78, 79 determination of potential 
protein binding partners and its expression in immune-privileged tissues.80 The 
presence of a leucine zipper motif suggests that CDR2 is involved in transcription or 
regulate gene expression, as proteins harbouring a leucine zipper motif dimerize to 
other proteins harbouring this motif and function primarily as transcriptional 
regulators.78, 81 Accordingly, proposed binding partners of CDR2, the serine-threonine 
protein kinase PKN, mortality factor-like protein MRGX, cell cycle related protein 
MRG15 and c-myc, are all involved in signal transduction or gene transcription.81-85 A 
model for CDR2 in PCD pathogenesis has been proposed based on its interaction with 
c-myc. CDR2 and c-myc forms a complex in Purkinje neuron cytoplasm that prevents 
c-myc from translocating to the nucleus, where it acts to promote transcription and 
transduction of neuronal signals.83 Binding of anti-Yo to CDR2 disrupts the CDR2-c-
myc interaction and thereby results in aberrant gene transcription, which leads to 
induced apoptotic cell death of Purkinje neurons.83  
CDR2 expression has been comprehensively studied at the mRNA and protein levels, 
as well as in cancerous and normal tissues. In 1997, Corradi et al., illustrated that the 
CDR2 protein expression is restricted to Purkinje neurons, brainstem neurons and 
testes in mice.80 Since the brain and testes previously were considered as immune-
privileged sites, these findings correspond well with the autoimmune model of PCD 
pathogenesis.80 In 2000, a study reported that approximately 60% of human ovarian 
cancers and 20% of human breast cancers expressed CDR2.86 Later, it was found that 
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CDR2 is also expressed in a type of kidney cancer, papillary renal cell carcinoma,87 
and in cell lines of lung, neuroblastoma, cervical, ovarian and colon cancer.88 These 
findings imply that the CDR2 protein is expressed in various cancers. Furthermore, 
CDR2 has also been found in normal ovary tissue, raising the question why anti-Yo 
associated PCD is restricted to the nervous system.88, 89  
An age dependent expression has been suggested based on western blot analysis of rat 
brain cortex, illustrating a down-regulation of the CDR2 protein after birth.90 A similar 
pattern has been shown for CDR2 at the mRNA level in human cerebellum.89 Overall, 
CDR2 mRNA is detected in nearly all tissues and this wider mRNA distribution 
compared to the protein, suggests that CDR2 undergoes post-translational 
modification, potentially phosphorylation by PKN or ubiquitination by anaphase-
promoting complex/cyclosome (APC/C).80, 84, 85 
The subcellular location of the anti-Yo antigen has been demonstrated by 
immunostaining of human and rat cerebellum sections using patient sera and an 
antibody from a PCD patient that showed 94% homology with the antigen recognized 
by Yo antibodies.91, 92 The results imply that CDR2 localizes to the cytoplasm, and 
associates with membrane-bound and free ribosomes, and potentially to the Golgi 
apparatus, in Purkinje neurons.    
For 30 years, research mainly focused on CDR2 as the main Yo antigen, partially based 
on the identification of CDR2 mRNA expressed in PCD-associated tumors.80 In 2013, 
CDR2L was introduced as a new player in PCD after showing that only patients with 
Yo positive sera that contained both CDR2 and CDR2L antibodies had PCD.75 
Localization studies have shown that CDR2L antibodies stain human Purkinje neurons 
in a granular cytoplasmic pattern, similar to anti-Yo.47, 75 In addition, CDR2L is more 
highly expressed in human Purkinje neurons than CDR2.75 Recent studies have shown 
that not only CDR2 but also CDR2L is widely expressed in normal tissues and PCD 
associated tumors.75, 89, 93 The exact subcellular localization of endogenous CDR2L is 
largely unknown, with only a proposed localization of recombinant CDR2L to the 
plasma membrane of transfected HeLa cells.75 According to the Atlas of the developing 
 36
human brain database (www.brainspan.org), CDR2L mRNA levels increase with age, 
the opposite trend of what has been shown for CDR2 mRNA.  
The CDR2 and CDR2L transcripts encode two proteins of 454 and 465 amino acids, 
with an estimated molecular weight of 62 kDa and 55 kDa, respectively (Appendices 
9.2 to 9.4). CDR2L contains potential coiled-coiled regions, similar to CDR2.75 Results 
from epitope mapping imply that anti-Yo do not recognize any common linear epitopes 
between CDR2 and CDR2L.94 
Pathophysiology  
The cellular and molecular mechanisms causing PCD pathogenesis is partially 
unknown. As for most or all PNS, PCD is also thought to be immune-mediated but the 
roles of humoral and cellular immunity is largely unresolved.47 Anti-Yo is mainly of 
the IgG1 subclass, present in higher titers in CSF compared to serum of PCD patients. 
This high CSF/serum ratio of Yo antibodies and the presence of CSF oligoclonal IgG 
bands suggest that there is an ongoing Yo antibody synthesis and activation of B 
cells.53, 95 However, the number of B cells detected in the cerebellum of post-mortem 
sections from PCD patients is low. This can merely be due to the patients already being 
at the final “burn-out” stage and that a humoral immune response may take place earlier 
in the pathogenesis.69, 96, 97    
The presence of antigen (CDR2)-specific CD8+ T cells have been reported in several 
studies of PCD patients,51, 52, 96 both in ovarian tumors and in autopsy studies of the 
human cerebellum.69 These observations have led to a proposed pathomechanism in 
which apoptotic tumor cells that express the antigen are phagocytosed by antigen-
presenting cells that migrate to the lymph nodes and activate antigen-specific cytotoxic 
T cells. Activated T cells can then migrate back to the tumor site and thus elicit the 
immune response, or potentially cross the BBB and attack Purkinje neurons.47, 51 
However, these findings were contradicted in later studies, in which CD8+ T cells 
specific for CDR2 could not be found.98, 99  
Greenlee et al., used organotypic slice cultures of rat cerebellum to show that 
administration of anti-Yo via serum, CSF or purified IgG resulted in Purkinje neuron 
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death, thus implying a direct damaging effect of Yo antibodies.100, 101 An adsorption 
experiment was performed to show that the observed cytotoxic effect was caused by a 
specific binding of anti-Yo to its antigen, CDR2.102 However, others found that co-
expression of CDR2 and CDR2L antibodies is necessary for rat Purkinje neuron 
staining and that the observed staining by Greenlee et al. (2010) most likely was due 
to the presence of CDR2L antibodies in the serum and CSF.75, 100   
Other studies have investigated the role of microglia in PCD. Despite extensive 
microglia activation in the human cerebellar white matter and the presence of microglia 
nodules in the Purkinje neuron layer of PCD patients,103 immunofluorescence studies 
of organotypic slice cultures of rat cerebellum suggest that microglia infiltration occurs 
after Purkinje neuron death.75, 102  
Another disease model suggests that dysregulation of calcium homeostasis upon anti-
Yo-antigen binding causes Purkinje neuron death.104 Incubating rat cerebellar 
organotypic slice cultures with human patient sera or rabbit CDR2 and CDR2L 
antibodies, leads to altered calcium buffering capacity due to calbindin malfunction 
and subsequent Purkinje neuron death.101, 104 
Several attempts to develop animal models that mimic PCD have failed.97 Guinea pigs, 
rats and mice injected with IgG from PCD patients show IgG immunoreactivity in 
Purkinje neuron cytoplasm but no clinical or pathologic evidence of Purkinje neuron 
loss.105-108 A mouse model of paraneoplastic diseases was generated, in which Purkinje 
neurons and implanted breast tumors expressed the same antigen, namely 
hemagglutinin.109 Mice were transferred with hemagglutinin-specific naive CD4+ and 
CD8+ T cells, which resulted in partial control of tumor growth. Using immune 
checkpoint therapy with anti-CTLA4 monoclonal antibody, mice were protected from 
tumor outgrowth but showed Purkinje neuron loss and neurological signs, such as 
reduced spontaneous locomotion and reduced motor activity.109 Infiltration of antigen-
specific T cells into the cerebellum upon CTLA4 blockade and the subsequent neuronal 
loss led to the assumption that CD8+ T cells play an important role in disease 
development. Despite illustrating the importance of T cell activation and effect of 
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immune checkpoint therapy in paraneoplastic disorders, this model does not fully 
mimic PCD pathogenesis with the absence of onconeural antibodies. 
Clinical features and diagnosis  
PCD is charactierzed by cerebellar Purkinje neuron loss, severe ataxia, nystagmus and 
dysarthria110. Patients with anti-Yo associated PCD usually present with subacute 
development of the cerebellar deficits, over a period of weeks to months.111 The disease 
affects women and the median age for onset is approximately 60 years.62 An 
international panel supported by the Paraneoplastic Neurological Syndrome 
Euronetwork proposed a list of recommended diagnostic criteria for PNS.17 Anti-Yo 
associated PCD falls under the category “classical” PNS, with a well-characterized 
antibody.  
Treatment 
As with other PNS, the neurological symptoms usually appear before the cancer has 
been identified. Antibody detection should therefore direct the search for an underlying 
neoplasm using computed tomography (CT) or with positron emission tomography 
(PET) scans if the CT is negative.110-112 Treatment of the neoplasm to stabilize the 
neurological symptoms are the cornerstone of therapy in PCD.103, 110 The use of 
immunotherapy, including rituximab, intravenous immunoglobulins and 





 AIMS OF THE STUDY 
The principal goal throughout the course of this work was to determine the major Yo 
antibody target, investigate the precise subcellular location of CDR2L and CDR2, and 
address the possibility of including CDR2L as diagnostic marker in routine clinical 
tests.   
 
Objectives: 
Paper I: The aim of this study was to determine whether CDR2 or CDR2L is the major 
target of Yo antibodies.  
 
Paper II: The aim of this study was to investigate the subcellular location of CDR2 
and CDR2L in cancer cells and Purkinje neurons, as well as potential protein binding 
partners.  
 
Paper III: The aim of this study was to address the value of including CDR2L as a 









 MATERIALS AND METHODS 
Primary antibodies included in this study were purchased from commercial companies. 
An overview is provided in Appendices, Table 9.1. 
3.1 Patient samples and ethical considerations  
Paper I and II  
Five sex- and age-matched CSF and serum samples from patients with Yo antibodies 
and five without Yo antibodies and no neurological disease or underlying cancer 
(negative controls) were used to stain human and rat cerebellar tissues, rat Purkinje 
neuron cultures and cancer cells. The samples were obtained from the Neurological 
Research Laboratory, Haukeland University Hospital (Regional Committee for 
Medical and Health Research Ethics in Norway, REK #2013/1480).  
Paper III  
In the period 2017 to 2020, 9527 sera and CSF samples were screened for onconeural 
antibodies at the Neurological Research Laboratory. Twenty-four patients showed Yo 
reactive bands on the commercial PNS 14 Line Assay from Ravo Diagnostika and were 
included in the study. Patient records were obtained and anonymized prior to the study 
and PCD was diagnosed according to established criteria (Regional Committee for 
Health and Medical Research Ethics in Norway, REK #123524). 
3.2 Cerebellar tissue  
Cerebellar sections were cut from fresh frozen normal human tissue (REK, 
#2013/1503) or from paraformaldehyde (PFA)-perfused rat brains (FOTS 




3.3 Cell cultures, recombinant DNA and transfection   
Paper I and II  
Cancer cell lines were maintained as a model system to investigate the subcellular 
location of proteins of interest and identify protein interaction partners by 
colocalization studies using STED microscopy and proximity ligation assay. OvCar3 
(American Type Culture Collection (ATCC), #HTB-161) and HepG2 (ATCC, #HB-
8065) cancer cell lines were maintained and subcultivated on poly-D-lysine-coated 
coverslips (Neuvitro, #GG-18-1.5-pdl) according to the manufacturer’s protocol. Cells 
were washed twice with 0.1 M phosphate-buffered saline (PBS), fixed (15 minutes, 4% 
paraformaldehyde in PBS, Thermo Fisher Scientific, #28908), and quenched (5 
minutes, 50 mM NH4Cl, Sigma-Aldrich, #254134) prior to immunostaining.  
OvCar3 and HepG2 cells were prone to transfection of full-length CDR2 (OriGene 
Technologies, Rockville, MD; #RG204900) and CDR2L (OriGene Technologies, 
#RC206909) ligated into a pCMV6-AC-GFP vector (OriGene Technologies, 
#PS100010). Following polymerase chain reaction, correct CDR2 and CDR2L vector 
sequences were confirmed using BioEdit v7.2.5. One Shot TOP10 Escherichia coli 
(Life Technologies, Carlsbad, CA; #C4040-10) were used for amplification, E.Z.N.A. 
Plasmid DNA Kit (Omega Bio-Tek, Norcross, GA, #D6942) for purification, and 
Lipofectamine 3000 (Thermo Fisher Scientific, #L3000008) for transfection.  
Paper III 
HEK293 cells were transfected with a plasmid for expression of Myc-DDK-tagged 
CDR2L (Origene, #RC206909) using Lipofectamine 3000 Reagent (Invitrogen, 
#L3000008). Cells were cultured in 8-well NuncTM Lab-TecTM II Chamber SlideTM 
System (Thermo Fisher Scientific, #154534) in Eagle’s Minimum Essential Medium 
supplemented with 10% fetal bovine serum and penicillin/streptomycin (37 °C, 5% 
CO2). At 48 h after transfection, coverslips were washed with PBS and fixed with 4% 
PFA/4% glucose in PBS (20 min, room temperature). Demembranation with 0.1% 
Triton X-100 in PBS (7 min, room temperature) was followed by blocking with 10% 
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Sea Block blocking buffer (Thermo Fisher Scientific, #37527) in PBS (1 h, room 
temperature), prior to immunostaining.  
3.4 Immunostaining   
OvCar3 and HepG2 cells and cerebellar sections were permeabilized in 0.5% Triton 
X-100-PBS (Sigma-Aldrich, #11332481001, 5 minutes), washed in 0.5% gelatin-PBS 
(Sigma-Aldrich, #G7041, 5 minutes), blocked in 10% SEABLOCK (Thermo Fisher 
Scientific, #37527, 30 minutes) in PBS and incubated with primary antibodies 
overnight at 4 °C. Following incubations, cells and sections were washed in gelatin-
PBS, incubated with secondary antibodies for 2 hours at room temperature, and 
mounted using ProLong Diamond with DAPI (Thermo Fisher Scientific, #P36962). 
3.5 Immunoprecipitation  
Immunoprecipitation was performed to evaluate the co-reactivity of CDR2L and Yo 
antibodies, to investigate potential protein interaction partners of CDR2 and CDR2L, 
as well as determining the specificity of numerous CDR2 and CDR2L antibodies, 
confirmed by mass spectrometry analysis. Proteins of interest were 
immunoprecipitated from OvCar3 and HepG2 cell lysates using Protein G Magnetic 
Beads (Dynabeads, Thermo Fisher Scientific, #1004D), as described in the Bio-Rad 
SureBeads immunoprecipitation protocol. The reaction products were detected by 
sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE), followed 
by western blot analysis. A negative control consisting of beads and cancer cell lysate 
was also included in each experiment.  
3.6 Western blot analysis  
Proteins of interest in whole cell lysates of immunoprecipitation products were 
subjected to SDS-PAGE separation on a 10% TGX gel (Bio-Rad, #456-1035), and 
transferred to a polyvinylidene difluoride membrane using the Trans-Blot Turbo 
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Transfer kit (Bio-Rad, #170-4274). The blots were blocked in 5% dry-milk (Bio-Rad, 
#170-6404) dissolved in 1x Tris-buffered saline with 0.1% Tween 20 (TBS-Tween 20), 
and incubated with serum/CSF samples from patients or antibodies, diluted in 3% BSA 
in TBS-Tween 20 (1:250 for sera and 1:100 for CSF, 4 °C, overnight). Antibody 
fixation was visualized using horseradish peroxidase anti-human IgG (Dako, #P0214, 
1 h, room temperature).  
3.7 Fluorescent immunoblotting 
Cerebellar and cancer cell lysates were obtained using a Total Protein Extraction Kit 
(Millipore, Billerica, MA; #2140). Proteins were separated on a 10% TGX gel and 
transferred to a low autofluorescence PVDF membrane. G:Box (Syngene, Frederick, 
MA) was employed for visualization. 
3.8 Mass spectrometry-based proteomics analysis  
Mass spectrometry-based proteomics was used to evaluate the specificity of numerous 
CDR2 and CDR2L antibodies, and to screen for potential protein interaction partners. 
The proteins of interest were immunoprecipitated from OvCar3 and HepG2 cells and 
subjected to SDS-PAGE. Gel bands were cut into 1 mm2 cubes and hydrated in MilliQ 
water. The remaining procedure was performed at the Proteomics Unit in Bergen 
(PROBE), University of Bergen, Norway.114  
Proteins were identified after extracting the obtained mass spectra data with Proteome 
Discoverer (version 2.3.0.523, Thermo Fisher Scientific), followed by searching 
against human, reviewed protein sequences (SwissprotKB database, release 08-2018) 
with Sequest HT and MS Amanda search engines. In order to evaluate the likelihood 
of the predicted interactions, the following criteria were established: 1) nonspecific 
bindings were removed based on the negative control; 2) the number of recognized 
peptides was set to at least two; 3) proteins that were identified by more than one of 
the antibodies to CDR2L or CDR2 were considered as more likely partners; 4) the 
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likelihood of an interaction was evaluated based on the predicted cellular location of 
CDR2/CDR2L. Protein-protein interactions were analyzed using the STRING 
database.  
3.9 Super-resolution microscopy  
A Leica TCS SP8 Stimulated Emission Depletion (STED) 3X confocal microscope 
equipped with a 100x oil objective with a numerical aperture of 1.4 was used for 
imaging. The output of the excitation laser (up to 1.5 mW per line; pulsed) was kept 
between 1% and 20% and the STED laser (775 nm; up to 1.5 W) between 20% and 
30%. Gating (between 1 and 6 ns) was applied for all channels as well as a minimum 
of three intensity averages. The lateral resolution was consistently measured to be 
between 40 and 50 nm. All experiments were run with negative controls, containing 
only secondary antibodies, simultaneously for laser intensity thresholding. 
3.10 Proximity ligation assay  
Potential interaction partners of CDR2 and CDR2L, identified by mass spectrometry 
analysis, were further evaluated by colocalization studies, including proximity ligation 
assay. The available Duolink kit from Sigma-Aldrich (#DUO92101) was used to 
identify interaction partners within a 40 nm range in OvCar3 cells. Fixed OvCar3 cells 
were permeabilized using 0.5% Triton X-100 diluted in PBS, blocked with 10% 
SEABLOCK in PBS and incubated with primary antibodies in blocking solution. Cells 
were washed with Wash buffer A, before and after incubation with probes (+ and -). 
Then, cells were incubated with ligation buffer (1:5) and ligase enzyme (1:40), 
followed by washes with Wash Buffer A. Amplification buffer (1:5) and the 
polymerase enzyme (1:80) were diluted in distilled water and applied to the cells for 
100 minutes (37 °C, in the dark), followed by washes with Wash Buffer B (supplied 
with the kit). Prolong Diamond with DAPI was used to mount the coverslips 
(overnight, 4 °C). Mounted cells were stored at -20 °C.  
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3.11 Commercial line immunoassays  
We used the commercial line immunoassays PNS 14 Line Assay (Ravo Diagnostika, 
#PNS14-003) and EUROLINE PNS 12 Ag (Euroimmun, #DL1111-1601-7-G) to 
detect onconeural antibodies in patients with suspected PCD. Patient samples that 
showed Yo reactive bands on the PNS 14 Line Assay, was further evaluated by 
EUROLINE PNS 12 Ag. Two independent investigators graded band intensities from 
+ to +++, compared to a positive control sample (+++).   
Serum and CSF from the patients with Yo reactive bands were also tested for anti-Yo 
using a commercial CBA (Purkinje Cell Mosaic 1, Euroimmun, #FA1113-1005-1) 
consisting of BIOCHIP Mosaics with four positions (Yo/CDR2-, Tr/DNER-, ITPR1- 
and CARP-transfected HEK293 cells). Aliquots of 30 µl serum (diluted 1:100) or of 
CSF (diluted 1:1) were applied to each reaction field on the BIOCHIP slide. After 
incubation (30 min, room temperature), the slide was washed with PBS-Tween 20 (5 
min, room temperature), followed by incubation with secondary antibody (30 min, 
room temperature). The slide was rinsed with PBS-Tween 20, and mounted on a glass 
coverslip. The cut-off for Yo/CDR2 was set to 1:100, as advised by the manufacturer. 
Two independent investigators evaluated the results. 
3.12 Imaging processing  
Rat cerebellar sections and CBAs were imaged on a Leica Leitz DMRBE fluorescence 
microscope with CoolLED pE-300-W LED illumination. Images were evaluated by 2 
independent investigators. ImageJ was used for background subtraction of microscopy 
images and evaluation of western blot results.  
3.13 Methodological considerations  
Patient cohort  
The main limitation to the work presented in paper III, is the small patient cohort. Out 
of the 9,527 patient sera and CSF samples screened for onconeural antibodies at 
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Haukeland University Hospital, only six of these were diagnosed with anti-Yo 
associated PCD. Samples were selected on CDR2-positivity and we do not know 
whether testing for CDR2L antibodies alone would be sufficient. A follow up study 
including a larger patient cohort including PCD patients who test negative in 
commercial line immunoassays and patients with PNS caused by other paraneoplastic 
antibodies should be performed to evaluate the strength of our findings. However, 
despite the small cohort, our data demonstrate that including CDR2L as a diagnostic 
marker adds an important dimension to the accuracy of PCD testing.    
Interpretation of immunofluorescence results  
Immunofluorescence of rat cerebellar tissue is a suitable confirmatory test for PCD 
diagnosis but it is also a laborious approach that requires access to proper equipment. 
When interpreting immunofluorescence results, it is important to be aware that it is to 
some degree considered as a semi-quantitative method that cannot determine the 
absolute amount of protein available in the sample.115 Thus, the relationship between 
staining intensity and antigen quantity is non-linear and a measure of the staining 
intensity will not simply reflect the severity of the disease. Furthemore, interpretation 
of the characteristic, granular staining pattern of Purkinje neurons must be handled with 
caution since false positive anti-Yo staining can be presented with a cytoplasmic but 
non-granular pattern, unrelated to PCD. To mitigate this limitation, we developed CBA 
for CDR2L as an alternative approach.     
Antibody based methods  
The majority of experimental techniques used in these projects depend on commercial 
antibodies. There has been an increasing focus on the limitations regarding the use of 
antibodies for research purposes, due to poor validation, unspecificity, low 
reproducibility and batch-to-batch variabilities.116, 117. It was therefore important to 
perform antibody validation of our available CDR2 and CDR2L antibodies, especially 
after observing considerable variations in staining patterns. For further discussion on 




4.1 Paper I: CDR2L Is the Major Yo Antibody Target in 
Paraneoplastic Cerebellar Degeneration 
In paper I, we investigated whether CDR2 or CDR2L is the major target of Yo 
antibodies. CSF and serum from PCD patients, and CDR antibodies were used to stain 
human and rat cerebellar sections. CDR2L showed a cytoplasmic staining pattern in 
Purkinje neuron somas that overlapped with the Yo antibody staining from patient CSF 
and serum (Fig 4.1 A and B). An overlapping staining pattern of CDR2L and Yo was 
also observed in stellate and basket cells (Fig 4.1 C). CDR2 mainly stained the nucleus 
of Purkinje neurons and no overlap with Yo antibodies was detected (Fig 4.1 A, B and 
C). Fluorescent immunoblot of rat cerebellar lysate showed that CDR2L and Yo stain 
the same 55 kDa band, whereas CDR2 stains a 62 kDa band that does not overlap with 
Yo (Fig 4.1 D).   
OvCar3 cells express CDR2L and CDR2 endogenously. Colocalization studies using 
STED microscopy showed the same pattern as observed in Purkinje neurons. CDR2L 
and Yo colocalized in OvCar3 cell cytoplasm, whereas CDR2 staining did not overlap 
with Yo. Fluorescent immunoblot and immunoprecipitation confirmed these results.  
HepG2 cells, which express high levels of CDR2 endogenously, were transfected with 
recombinant, GFP linked CDR2 and CDR2L. We found that CDR2L and Yo antibodies 
colocalized in CDR2L-GFP transfected HepG2 cells, whereas the CDR2 antibody did 
not bind the recombinant CDR2L protein. Yo and CDR2 antibodies were not able to 
bind in untransfected cells. Only upon CDR2-GFP transfection was Yo and CDR2L 




Figure 4.1:  Yo antibodies bind to CDR2L, but not CDR2, in cerebellar Purkinje cells. Scale bars = 10μm. (A) 
Sections of fresh frozen human cerebellum. Upper row: Section stained with Yo (cerebrospinal fluid [CSF]; 
green) and anti-CDR2L (red); the antibodies colocalize in the cytoplasm (seen as yellow in the merge image). 
Lower row: Section stained with Yo (CSF; green) and anti-CDR2 (red); no colocalization is seen between Yo 
and CDR2. (B) Sections of paraformaldehyde (PFA)-perfused rat cerebellum. Upper row: Section stained with 
Yo (CSF; green) and anti-CDR2L (red); CDR2L colocalize with Yo. Lower row: Section stained with Yo (CSF; 
green) anti-CDR2 (red); no colocalization is seen. (C) Sections of PFA-perfused rat cerebellum. Upper row: 
Section stained with Yo (serum; green) and anti- CDR2L (red); Yo and CDR2L colocalize in the Purkinje cells 
(outlined) as well as in the stellate and basket cells (arrows). Lower row: Section stained with Yo (serum; green) 
and anti-CDR2 (red); no colocalization is seen between Yo and CDR2. These images are a z-stack merge, as not 
all stellate/basket cells were in the same focal plane as the Purkinje cells; thus, the cytoplasmic staining found 
over or under the nuclei may appear nuclear although it is not (eg, the Yo serum staining is not nuclear). (D) 
Fluorescent immunoblot of rat cerebellar lysate. Anti-CDR2L and Yo (CSF) stain the same band at 55kDa; anti-
CDR2 does not. Secondary antibody controls were negative.118 
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4.2 Paper II: Localization of CDR2L and CDR2 in 
paraneoplastic cerebellar degeneration 
To ensure antibody specificity, CDR2L and CDR2 were immunoprecipitated from 
OvCar3 and HepG2 cell lysates, respectively, and analyzed by mass spectrometry-
based proteomics. We found that all of our commercially available antibodies were 
specific for their targets. Yo antibodies only precipitated CDR2L and confirmed our 
data from paper I, identifying CDR2L and the major Yo antibody target.  
Based on mass spectrometry analysis, we also identified potential binding partners of 
CDR2L and CDR2. Numerous ribosomal proteins, including the ribosomal protein S6 
(rpS6), were the most prominent CDR2L binding partners (Fig 4.2.1 A), whereas 
nuclear speckle proteins, SON, serine/arginine-rich splicing factor 2 (SRSF2) and 
eukaryotic initiation factor 4A-III (eIF4A3) were identified as potential binding 
partners of CDR2 (Fig. 4.2.1 B).  
 
Figure 4.2.1: Protein-protein interaction networks visualized by STRING. (A) CDR2L was predicted to interact 
with ribosomal proteins (rpS6, red box). The nodes indicate proteins, and the edges represent protein-protein 
associations. (B) Protein-protein interaction network of nuclear speckles proteins, SON, eIF4A3, and SRSF2, 
predicted to interact with CDR2. eIF4A3 (red) directly interacts with SON (light green) and SRSF2 (blue). Color-
coded edges; light blue: curated databases, dark blue: gene co-occurrence, pink: experimentally determined, 
green: text mining. Interactions with a medium score of 0.400 or more are shown.114 
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Colocalization studies using STED microscopy, co-immunoprecipitation and 
proximity ligation assay confirmed rpS6 as a binding partner of CDR2L (Fig 4.2.2 A) 
and that CDR2 is in direct contact with eIF4A3 and SON (Fig 4.2.2 B). eIF4A3 can 
translocate from the nucleus to the cytoplasm to aid in mRNA binding to the 40S 
ribosomal subunit, in conjugation with other initiation factors.119 We therefore 
proposed a model for CDR2 and CDR2L involvement in protein synthesis and that Yo 
antibody binding to CDR2L could result in altered or impaired functions of the 
ribosomal machinery or protein synthesis in patients with PCD.   
 
Figure 4.2.2: CDR2L co-immunoprecipitates with ribosomal protein rpS6, whereas CDR2 co-immunoprecipitates with 
nuclear speckle proteins SON and eIF4A3 in cancer cell lysates. (A) Immunoblot demonstrating the co-immunoprecipitation 
of CDR2L and rpS6 from OvCar3 cell lysates. (B) Immunoblot demonstrating the co-immunoprecipitation of CDR2, SON, 
and eIF4A3 from HepG2 cell lysates. Input = cancer cell lysates (OvCar3 or HepG2). Beads + lysate = samples that were not 
treated with primary antibody, and served as negative controls.114 
4.3 Paper III: Paraneoplastic cerebellar degeneration: the 
importance of including CDR2L as a diagnostic marker 
After identifying CDR2L as the major Yo antibody target and determining the 
subcellular location of the CDR proteins and binding partners, we aimed to evaluate 
the commercial tests used to diagnose patients with anti-Yo associated PCD. CDR2 
was previously considered as the main Yo antigen and commercial line immunoassays 
and cell-based assays therefore use CDR2 as the target, but with low specificity.44, 61 
From 2017 to 2020, we screened 9,527 patient sera and CSF for onconeural antibodies. 
Twenty-four patients showed Yo reactive bands (0.25%) on the commercial PNS 14 
Line Assay from Ravo Diagnostika, and were included in the study. Positive samples 
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were tested with EUROLINE PNS 12 Ag, CBA for CDR2 and indirect 
immunofluorescence of rat cerebellar sections. Yo positive sera from six PCD patients 
showed granular, cytoplasmic staining in Purkinje neurons. In the group of 18 non-
confirmed PCD cases, serum samples from two patients (7 and 8) stained Purkinje 
neurons but with no granular cytoplasmic staining; these patients were therefore 
interpreted as anti-Yo negative. The remaining 16 serum samples were negative.  
We developed two in-house techniques for CDR2L detection: a CBA consisting of 
HEK293 cells transfected with a plasmid that expressed Myc-DDK-tagged CDR2L and 
a western blot based analysis of recombinant CDR2 and CDR2L proteins. To evaluate 
the specificity of the CDR2L CBA, transfected HEK239 cells were stained with anti-
DDK, anti-CDR2L, or anti-CDR2 (Fig 4.3.1). No cross-reactivity was observed 
between CDR2 and CDR2L antibodies.  
Figure 4.3.1: No cross-reactivity is observed between CDR2 antibodies and CDR2L in human embryonic kidney 
293 cells that express Myc-DDK-tagged CDR2L. Upper row: cells stained with anti-CDR2L (green) and anti-
DDK (red). Lower row: cells stained with anti-CDR2 (no reaction), and anti-DDK (red). Nuclei are stained with 
DAPI. Scale bar = 20 μm. CDR2 = cerebellar degeneration-related protein 2; CDR2L = cerebellar degeneration-
related protein 2-like.120 
Samples from the 6 confirmed PCD cases stained both CDR2L-transfected cells, 
commercial CBA for CDR2 and identified recombinant CDR2L (55 kDa) and CDR2 
(62 kDa) in western blot analysis (Fig 4.3.2 A.a, A.b and A.c). The 7 patients with CBA 
CDR2-positive staining, but no PCD, were negative in the CBA for CDR2L (Fig 4.3.2 
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B.a and B.b). These results were confirmed by western blot analysis, which identified 
only recombinant CDR2 (62 kDa) in patient sera (Fig 4.3.2 B.c).  
 
Figure 4.3.2: Representative images of patient sera (1:100) double positive for CDR2L and CDR2 (A.a–A.c), and single 
positive for CDR2 (B.a–B.c) in indirect immunofluorescence of CDR2L transfected human embryonic kidney 293 Cells (A.a, 
B.a), commercial CBA for CDR2 (A.b, B.b), and WB (A.c, B.c). A negative control containing reticulocyte lysate without 
recombinant protein was included in each experiment. Anti-CDR2/CDR2L, green; anti-DDK, red; merge, yellow. Scale bar 
= 20 μm. CBA, cell-based assay; CDR2, cerebellar degeneration-related protein 2; CDR2L, cerebellar degeneration-related 





5.1 Paper I: CDR2L Is the Major Yo Antibody Target in 
Paraneoplastic Cerebellar Degeneration 
We demonstrated that CDR2L is the major Yo antigen target in PCD, as Yo antibodies 
in patient CSF and serum consistently reacted with CDR2L in human and rat cerebellar 
tissue, and in cultured cancer cells.  
Even though the CDR2L amino acid sequence was determined in 1996, it took about 
two decades before CDR2L was introduced as a new player in PCD.75, 76 CDR2 was 
previously considered as the main antigen, partially based on the identification of only 
CDR2 mRNA expressed in PCD-associated tumors.80 However, recent studies showed 
that both CDR2 and CDR2L are widely expressed in normal as well as PCD tumors, 
and that the CDR2L protein is overexpressed in the majority of Yo-PCD ovarian 
cancers.89, 93 These findings and the fact that CDR2L staining of cerebellar tissue with 
commercial antibodies highly resembled that of anti-Yo, led to the speculation that 
CDR2L could be the major antigen in anti-Yo associated PCD.  
Co-localization studies showed that CDR2L and Yo antibodies gave granular, 
cytoplasmic staining patterns that overlapped in human and rat Purkinje neurons, and 
in stellate and basket cells. A similar staining pattern was not found for CDR2, mainly 
localizing to the neuronal nuclei. These results were in line with previous experiments, 
in which Yo antibody reactivity in Purkinje neurons was abolished upon preabsorption 
with recombinant CDR2L, but only partially with recombinant CDR2.75 Another study 
showed that recombinant CDR2 absorbed Yo antibodies from positive sera, thereby 
abolishing Purkinje neuron cytotoxicity.102 There are potentially two main explanations 
for this discrepancy. First, the authors did not specify if anti-Yo was also absorbed with 
recombinant CDR2L. Second, there is a reactivity between recombinant CDR2 and Yo 
antibodies. The fact that recombinant CDR2 is used in routine diagnostic tests for PCD 
supports the latter. Therefore, we transfected HepG2 cells with CDR2 and CDR2L, and 
established that Yo antibodies can also bind recombinant CDR2.  
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The fact that CDR2 can be detected in a recombinant but not native form by Yo 
antibodies suggest that the epitope is inaccessible, most likely due to post-translational 
modification of CDR2 or by binding partners. Previous research suggests that CDR2 
is phosphorylated by PKN and potentially targeted for degradation via ubiquitination.83, 
84 Furthermore, anti-Yo is recognized by recombinant CDR2 on commercial line 
immunoassays, and only patients with Yo antibodies towards both recombinant CDR2 
and CDR2L develop PCD.75, 120 These findings suggest that Yo antibodies harbor a 
paratope against a common epitope shared between CDR2 and CDR2L. Data from 
phage display immunoprecipitation and sequencing, used to create a high-resolution 
epitope profile from anti-Yo patients, show that there are no common linear epitopes 
between CDR2 and CDR2L.94 It follows that any common epitope is most likely 
conformational, and more in depth knowledge on the 3D structure of the proteins is 
necessary to make any final conclusions.  
Based on ours and recent findings we have shown that CDR2L is the major Yo antibody 
target but we cannot exclude an additional role of CDR2 in PCD.  
5.2 Paper II: Localization of CDR2L and CDR2 in 
paraneoplastic cerebellar degeneration 
With a few exceptions, our knowledge in terms of the biological functions of CDR2 
and CDR2L is limited. Therefore, our goal was to establish the subcellular localization 
of CDR2 and CDR2L, and identify potential protein binding partners.  
5.2.1 CDR2 expression and interaction with nuclear speckle 
proteins  
It has become evident that several of the commercially available antibodies show 
varying staining patterns, localizing CDR2 to the cell cytoplasm and nucleus.88, 118 
Immunoprecipitation followed by mass spectrometry analysis confirmed that our 
antibodies are specific for their antigens. The discrepancy in the staining pattern may 
stem from the antibodies recognizing one of the five CDR2 isoforms (Appendices, Fig. 
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9.2) or from translocation of CDR2 between the cytoplasm and nuclei. Previous results 
imply that CDR2 translocate or facilitate transport of its proposed binding partners; c-
myc, PKN, MRG15 and MRGX.81, 82, 84, 85, 121 Another proposed mechanism is that 
phosphorylation of CDR2 impacts its subsequent degradation, initiated via APC/C-
mediated ubiquitination in gynaecologic tumor cells. This is of importance as it is 
suggested that CDR2 in its unphosphorylated form during mitosis interacts with c-myc 
and regulates tumor cell growth. Inappropriate CDR2 expression might affect c-myc-
dependent transcription during spindle formation and proliferation.84  
The fact that numerous studies suggest both a cytoplasmic and nuclear localization of 
CDR2 in neuronal and cancer cells strongly support the hypothesis that CDR2 is tightly 
regulated via post-translational modification, exists in several isoforms and/or 
translocate based on the cellular milieu.  
We identified three nuclear speckle proteins as potential binding partners of CDR2, by 
immunoprecipitation and mass spectrometry based proteomics; SON, SRSF2 and 
eIF4A3. Nuclear speckles are self-assembled clusters of around 200 proteins involved 
in pre-mRNA processing including splicing, surveillance, and RNA export. The 
speckles can vary in size and morphology within a single cell, but non-random 
organizations of proteins and RNAs occur, stabilized by intermolecular interactions.122 
SRSF2 and SON have domains enriched with arginine and serine repeats that are 
crucial for speckle core formation.122, 123 Both proteins are also involved in mRNA 
splicing124, 125 and interact with the ATP-dependent RNA helicase eIF4A3.126 Based on 
STED microscopy, proximity ligation assay and co-immunoprecipitation we 
confirmed that CDR2 interacts directly with SON and eIF4A3. 
Interestingly, SRSF2 can self-associate with SRSF1 (www.uniprot.org/Q01130), a 
protein that contributes to the oncogenic effect of myc.127 SRSF1 cooperates with myc 
to increase eIF4E activation, and promotes formation of aggressive breast tumors in 
humans.128 One can therefore speculate whether CDR2 could exert an oncogenic 
effect84 through its involvement in this complex network of proteins that upon 
activation, overexpression or dysregulation contribute to tumorigenesis.       
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5.2.2 CDR2L expression and interaction with ribosomal proteins 
We found that CDR2L specifically localizes to the cytoplasm of ovarian cancer cells, 
human and rat Purkinje neurons. Numerous ribosomal proteins were identified as 
potential binding partners of CDR2L based on immunoprecipitation-mass 
spectrometry data. Confirmatory tests showed that CDR2L co-immunoprecipitate and 
directly interacts with the ribosomal protein rps6. Rps6 is a component of the small 
(40S) subunit of ribosomes, and has mainly been studied due to rps6 being the first 
identified ribosomal protein to undergo phosphorylation.129 The phosphorylation state 
of rps6 can be used to monitor neuronal activity, based on increased rps6 
phosphorylation being reported during synaptic plasticity.129   
Our findings are in line with previous analysis of PCD patient sera, localizing Yo 
antibodies to the cytoplasm in association with membrane-bound and free ribosomes.91, 
92 Here, CDR2 is referred to as the Yo antigen, but based on the results published in 
paper I and the fact that Yo antibodies only precipitated CDR2L and not CDR2 in 
immunoprecipitation-mass spectrometry analysis, we are confident that CDR2L is the 
major Yo antigen. This is also in line with a recent publication which suggests that 
CDR2L is the immunodominant antigen in PCD patients.94      
5.2.3 CDR2 and CDR2L involvement in protein synthesis  
We have shown that CDR2 interacts with eIF4A3 in nuclear speckles. eIF4A3 can 
translocate from the nucleus to cytoplasm, and facilitate mRNA binding to ribosomes, 
along with other initiation factors.119 Affinity-capture mass spectrometry data imply 
that eIF4A3 interacts with rps6 in the cytoplasm.130 Since CDR2L binds to rps6, we 
suggest that CDR2 and CDR2L are linked in protein synthesis via a common pathway 
(Fig 5.2.3), in which CDR2 is involved in transcription and CDR2L in translation. 
Dysregulation of protein synthesis is associated with cancer and several neurological 
disorders.131 We have therefore proposed a model for CDR2 and CDR2L involvement 
in anti-Yo associated PCD pathogenesis, in which binding of anti-Yo to CDR2L in 
Purkinje neurons interferes with the ribosomal machinery, resulting in disrupted 
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mRNA translation and protein synthesis. These events should be tracked in real-time 
to further address the dynamic interaction between the CDR proteins and their function 
in Purkinje neuron deterioration.   
Based on immunoprecipitation-mass spectrometry analysis, CDR2 and CDR2L are not 
cross-reactive, suggesting that the antibody responses to each protein are 
independent.94 This is in line with our findings in paper I, demonstrating that there is 
no cross-talk between the proteins in their native forms.  
.  
Figure 5.2.3: Hypothesis of CDR2L and CDR2 involvement in protein synthesis in Purkinje neurons. CDR2 
localizes to the nucleus and directly interacts with nuclear speckle protein eIF4A3. eIF4A3, in conjugation with 
other cytoplasmic initiation factors, facilitates mRNA binding to the 40S ribosomal subunit. This event is 
important for mRNA maturation and translation, ultimately resulting in the synthesis of new proteins. CDR2L 
interacts with ribosomal subunit protein rpS6; therefore, we propose that CDR2L and CDR2 are both involved 
in the process of protein synthesis. Furthermore, Yo antibody (green) binding to CDR2L in Purkinje neurons of 
PCD patients may, therefore, interfere with the function of the ribosomal machinery, resulting in disrupted 
mRNA translation and/or protein synthesis.114 
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5.2.4 Antibodies: friend or foe? 
We have found that commercial antibodies against CDR2 and CDR2L give divergent 
results amongst various experimental techniques. Therefore, we performed 
immunoprecipitation followed by mass spectrometry analysis to evaluate the 
specificity of several CDR2 and CDR2L antibodies produced to recognize the full-
length protein or shorter sequences.  
Antibodies are amongst the most frequently used tools in biology laboratories but 
proper antibody validation across research applications is lacking. There are a number 
of factors to consider when buying commercial antibodies for research purposes. 
Antibodies that perform well in one context may perform inadequate in others due to 
differences in protein conformation and target accessibility. Proteins are in near-native 
form in immunoprecipitation, but they are unfolded or denatured in western blot 
analysis.116 Even small changes in sample preparation can have a large impact on how 
the antibody works.117  
Data regarding antibody function provided by companies may stem from cell lines that 
have been engineered to express the protein at higher levels than under physiological 
conditions. Thus, researchers should ideally test if the antibody can detect the protein 
of interest at physiological levels in the desired technique and in the material they plan 
to use.117 Off-target binding can occur if there is an antibody interest to proteins in the 
sample other than the target protein it was intended for. This holds even if the 
antibody`s affinity for other proteins is lower than it is for the target protein.116     
Whether to use monoclonal or polyclonal antibodies will in part depend on the 
application. Polyclonal antibodies are particularly useful for immunoprecipitation as 
they recognize several antigen epitopes, thereby forming a large precipitating lattice.39 
A monoclonal antibody can then be used during confirmatory analysis, such as western 
blot, providing specificity for the protein of interest. Variabilities from batch-to-batch 
or lot-to-lot can occur, and happens to a much larger extent for polyclonal antibodies 
compared to monoclonal.132      
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Another growing concern is the high percentage (43%) of unidentifiable antibodies in 
published scientific articles.117 This greatly impacts the ability to replicate already 
published work. An identification system has therefore been developed to uniquely 
identify antibodies, materials, reagents and tools with an ID called a Research Resource 
Identifier.116, 133   
5.3 Paper III: Paraneoplastic cerebellar degeneration: the 
importance of including CDR2L as a diagnostic marker 
The most established commercial tests for onconeural antibody detection, line 
immunoassay and CBA, use CDR2 as the Yo antibody target. However, recent studies 
pinpoint the low specificity of these tests, with a confirmation of approximately 6%.44, 
61 A potential reason for the high false positive rate is the use of CDR2, which is not 
the natural Yo antigen. Line immunoassays still detect Yo antibodies because anti-Yo 
bind recombinant CDR2, as shown in paper I. We found a discrepancy between the 
two commercial line immunoassays from Ravo Diagnostica and Euroimmun, most 
likely related to differences in use of CDR2 sequence length, and choice of cell line for 
production of recombinant CDR2. By combining results from the line immunoassays 
with CBA for CDR2, the number of false positive tests for PCD was reduced.  
Rat cerebellar immunofluorescence is the most accurate amongst the well-established 
tests, based on our own experience. However, many clinical laboratories are not 
equipped to perform immunofluorescence assays and the granular cytoplasmic staining 
of Purkinje neurons, which is characteristic for anti-Yo, can be difficult to interpret. As 
stated in paper II, this granular staining most probably represents the ribosomal staining 
reflecting CDR2L binding to rpS6.114  
We detected two samples from patients without PCD but with previous cancer that 
stained Purkinje neurons in a non-granular pattern. These samples can easily be 
detected as false positives for an untrained eye and the cytoplasmic staining must 
therefore be interpreted with caution, because it can be unrelated to PCD. Moreover, 
clinical features should also be taken into account to prevent misdiagnosis, unnecessary 
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testing and incorrect treatment. The number of false positive samples can also be 
reduced by performing immunohistochemistry as the initial screening, instead of line 
immunoassay or CBA. However, these analyses are laborious and require trained 
personnel to interpret staining patterns.     
We developed two in-house techniques, CBA for CDR2L and western blot analysis 
with recombinant CDR2 and CDR2L proteins, to evaluate the advantage of including 
CDR2L as a diagnostic marker for anti-Yo associated PCD. CBA for CDR2L was the 
only technique that could identify the PCD patients with 100% accuracy. Western blot 
analysis was not as accurate as CDR2L CBA and this discrepancy could be differently 
expressed epitopes of CDR2L detected in each of the assays. However, the western 
blot analysis detected fewer false positive samples compared to the line immunoassays.     
Although our study cohort is small our data demonstrate that detection of CDR2L is 
important to increase the diagnostic accuracy for Yo antibody detection. We do not 
know whether testing for CDR2L antibodies alone would be sufficient for diagnosis of 
PCD because our cohort was selected based on anti-CDR2 positivity. This question 
will require larger patient cohorts including PCD patients who test negative in 
commercial line immunoassays and patients who have PNS caused by other 
paraneoplastic antibodies.   
5.4 General discussion of PCD 
The main cornerstones in understanding PCD pathogenesis is to unravel the 
mechanisms underlying immune cell trafficking into the CNS and the potential 
pathogenic effect of paraneoplastic antibodies and immune cells on Purkinje neuron 
death.  
The brain was previously viewed as an immune-privileged site protected by the BBB, 
in which infiltration of immune cells was considered forbidden and immune activation 
solely detrimental.134 These assumptions regarding the immune-privileged status of the 
CNS have been discussed, especially in connection with technological advances and 
an increased understanding of the complexity of the immune system.134 Identification 
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of a glymphatic system, and that activated T cells can cross the BBB in the absence of 
neuroinflammation suggest that trafficking across the BBB is a highly regulated 
process.26 
Despite these advances, development of animal models to study PCD pathogenesis 
have proven difficult and most probably reflect the complexity of this disease. 
Organotypic slice cultures of rat brain tissue and Purkinje neuron cultures from rats 
lack the complexity of the BBB but serve as alternative model systems.102, 104, 135  
Cumulative evidence highlights a key role of CD8 T cells in PCD. An important finding 
in the elucidation of an antigen-specific cytotoxic effect of CD8 T cells on Purkinje 
neuron loss has been the identification of up-regulated MHC class I molecule 
expression on Purkinje neurons during inflammation.109, 136 This provides an 
opportunity for CD8 T cells to recognize intracellular antigens expressed by Purkinje 
neurons. Still, definitive evidence for a direct cytotoxic T cell effect is lacking.  
The direct role of paraneoplastic antibodies in PCD pathogenesis is also unclear. The 
fact that anti-Yo targets intracellular antigens and failed attempts to produce animal 
models upon IgG treatment have led to the assumption that Yo antibodies unlikely 
contributes to the neuronal loss.137 However, a direct cytotoxic effect on Purkinje 
neurons has been documented in rat organotypic slice cultures upon incubation with 
anti-Yo positive patient sera and CSF.100, 102 Similar slice cultures have also been used 
to elucidate the mechanistic effect of anti-CDR2/CDR2L internalization causing 
altered calcium buffering capacity due to calbindin malfunction and subsequent 
Purkinje neuron death.101, 104  
In line with these observations, a recent study presents a mechanism for intracellular 
localization of systemic lupus erythematosus (SLE) autoantibodies.138 In the setting of 
endocytosis-mediated transport, the antibody binds to FcR or other binding partners 
and internalizes it into an endocytic vesicle that can be targeted for recycling, endo-
lysosomal- or proteasomal degradation. Endosomal escape of the SLE-derived 
antibody is mediated by increased H+ influx that results in enzyme activation and 
dissociation of the antibody from its binding partner (heparan sulfate proteoglycan). 
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The antibody can escape via a pore, formed by the increasing acidic milieu and 
subsequent membrane destabilization. Identification of IgG-FcγII receptors in Purkinje 
neurons and antibody uptake via Fcγ receptor endocytosis makes it tempting to 
hypothesize that anti-Yo can be internalized through similar mechanisms.139, 140    
The fact that CDR2 and CDR2L are widely expressed in normal tissues and all ovarian 
cancers regardless of the presence of Yo antibodies, suggests that CDR2/CDR2L 
expression alone is insufficient to trigger autoimmunity.89 The infrequent prevalence 
of anti-Yo associated PCD suggests that disease progression is most likely 
multifactorial, involving disruption of immune tolerance, genetic predisposition, 
mutations in the CDR2/CDR2L genes, B and T cell activation and trafficking into the 
CNS, a direct cytotoxic effect of Yo antibodies and/or as a side-effect of therapy with 
ICIs.56, 60, 93, 102, 109, 141 Further studies are necessary to unravel the in depth mechanisms 
involved in pathogenesis of anti-Yo associated PCD.  
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 ADVANCES AND FUTURE ASPECTS  
Establishing that CDR2L is the major Yo antibody target in PCD is of great importance, 
as future research should be focused on this antigen, rather than CDR2. The role of 
humoral and cellular mechanisms in PCD is still unknown. A discrepancy in findings 
related to the presence of CDR2 specific cytotoxic T cells has been observed.51, 52, 96, 98, 
99 It follows that it would be interesting to explore if a CDR2L specific cytotoxic T cell 
response is involved in PCD pathogenesis. Regarding Yo antibodies, future research 
should be focused on possible endocytic or FcR mediated transport of the antibodies 
into Purkinje neurons.         
The role of immune cells in anti-Yo associated PCD pathogenesis is not well 
established. The extensive loss of Purkinje neurons is proposed to be caused by a direct 
damaging effect of anti-Yo, infiltration of cytotoxic CD8+ T cells and activation of 
microglia. The development of imaging mass cytometry (IMC) enables simultaneous 
detection of over 40 markers on tissue sections.142 This technique couples traditional 
immunostaining approaches with metal-tagged antibodies and laser ablation. IMC can 
be used to study the presence, distribution, function and activation of immune cells in 
complex tissues, such as the human brain, and map cellular interactions. Including 
material from several brain regions would enable the study of the local and potentially 
systemic effect of immune responses in PCD pathogenesis.     
We have unraveled the subcellular localization of CDR2 and CDR2L. However, the in 
depth cellular functions of the proteins remain largely unknown. Further investigation 
of the proposed model for CDR2 and CDR2L involvement in protein synthesis will be 
important when elucidating the specific mechanisms causing Purkinje neuron loss in 
PCD. CRISPR/Cas9 or RNA interference technologies can be applied to knock out or 
knock down the target genes to study the functions of CDR2 and CDR2L and to further 
validate the commercially available antibodies. 
Development of a protocol for rat Purkinje neuron culture yields opportunities to 
further characterize PCD pathogenesis.135 These cultures are suitable for live-cell 
imaging of fluorescently tagged CDR2 and CDR2L, thus allowing investigation of 
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activity dependent CDR expression in depth, and their effect on Purkinje neuron 




Paper I: Establishing that CDR2L is the major Yo antibody target allows us to 
reconsider our view on the pathogenic mechanisms involved in PCD. The fact that anti-
Yo still binds CDR2 in its recombinant form suggests that CDR2 might play a vital 
role in PCD pathogenesis, but the exact biological functions and molecular 
mechanisms remain unresolved.  
Paper II: Previous research suggests that the Yo antibody target is localized in the cell 
cytoplasm in close association with ribosomes. We are confident that the observed 
staining pattern reflects the subcellular localization of CDR2L, being the major antigen 
found in sera and CSF of anti-Yo associated PCD patients. A proposed model for the 
involvement of CDR2 and CDR2L in protein synthesis is made based on the 
identification of protein binding partners. CDR2 is localized to the nuclear speckles in 
contact with eIF4A3, which can translocate to the cytoplasm and in cooperation with 
other initiation factors aid in mRNA binding to the ribosomes via its interaction with 
rps6. Since rps6 interacts with CDR2L, this provides a direct link between CDR2 and 
CDR2L. Whether these findings fully reflect the true nature of the CDR proteins and 
their functions remain to be resolved.   
Paper III: We developed two in-house techniques, CBA for CDR2L and western blot 
analysis using recombinant CDR2 and CDR2L, to demonstrate the importance of 
including CDR2L as a diagnostic marker. Commercially available tests for Yo 
antibody detection have low specificity because these assays use CDR2 as target. We 
show that the accuracy of PCD diagnosis is greatly improved by adding a test using 
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9.1 Commercial antibodies   
Table 10.1: Overview of antibodies used in scientific experiments in paper I-III.    
Paper  Antibody  Company Species  Catalog nr. Method 
Paper II, III CDR2 Sigma-Aldrich rb HPA023870 IP-MS, CBA 
Paper I, II CDR2 Sigma-Aldrich rb HPA018151 ICC, WB, IP-MS 
Paper II CDR2 Santa Cruz m Sc-100320 IP-MS 
Paper I, II CDR2 LSBio m C181958 ICC, WB, IP-MS 
Paper I, II, III CDR2L Proteintech rb 14563-1-AP ICC, IP, WB, IP-MS, CBA 
Paper II CDR2L Proteintech m 66791-1-Ig IP-MS 
Paper II CDR2L Sigma-Aldrich rb HPA022015 IP-MS 
Paper III DDK Origene m TA50011-100 CBA 
Paper II eIF4A3 Abcam rb 32485 WB 
Paper II eIF4A3 Santa Cruz m Sc-365549 ICC, WB 
Paper II Hsp60 Biotechnology c CPCA-HSP60 PLA 
Paper II rpS6 Cell Signaling m 2317 ICC 
Paper II rpS6 Santa Cruz m Sc-74459 ICC, WB 
Paper II SON  Santa Cruz m Sc-398508 ICC, WB 
Paper II SRSF2  Abcam m Ab11826 ICC 
CBA, cell-based assay; ICC, immunocytochemistry; IP-MS, immunoprecipitation-mass spectrometry analysis; 
PLA, proximity ligation assay; WB, western blot; c, chicken; m, mouse; rb, rabbit.  










(RefSeq: NP_001793.1, human, gene ID: 1039, 454 amino acids) 
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Table 10.2: CDR2 antibody immunogen sequences 
Target Source/Supplier Cat. no. AA seq. Species 
CDR2 Sigma-Aldrich HPA018151 270-392 rb 
CDR2 Sigma-Aldrich HPA023870 112-234 rb 
CDR2 Santa Cruz Sc-100320 296-405 m 




Figure 10.2: Predicted CDR2 isoform sequences (www.uniprot.org). H3BQS4, organge; H3BU23, yellow; 
H3BTR1, blue; H3BN65, green; H3BUE0, red.  










(RefSeq: NP_055418.2, human, gene ID: 30850, 465 amino acids) 
 
Table 10.3: CDR2L antibody immunogen sequences 
Target Source/Supplier Cat. no. AA seq. Species 
CDR2L Sigma-Aldrich HPA022015 395-464 rb 
CDR2L Proteintech 14563-1-AP 116-465 rb 
CDR2L Proteintech 66791-1-Ig 116-465 m 
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9.4 Aligned CDR2 and CDR2L amino acid sequences  






















Only three identical epitopes between CDR2 and CDR2L that are over six amino acids 
in length exist: 
1. LAAELGKTLL (10)                                
2. NEQHAKVYEQLD (12)       
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The pathogenesis of Yo-mediated paraneoplastic cerebellar
degeneration (PCD) is unclear. We applied cerebrospinal
fluid and serum from PCD patients as well as CDR2 and
CDR2L antibodies to neuronal tissue, cancer cell lines, and
cells transfected with recombinant CDR2 and CDR2L to elu-
cidate which is the major antigen of Yo antibodies. We
found that Yo antibodies bound endogenous CDR2L, but
not endogenous CDR2. However, Yo antibodies can bind
the recombinant CDR2 protein used in routine clinical test-
ing for these antibodies. Because Yo antibodies only bind
endogenous CDR2L, we conclude that CDR2L is the major
antigen of Yo antibodies in PCD.
ANN NEUROL 2019;00:1–6
Paraneoplastic cerebellar degeneration (PCD) is one ofthe most common paraneoplastic neurological syn-
dromes.1 In PCD patients, the immune system targets a tumor
antigen that is also expressed endogenously in the nervous sys-
tem.2 Among the most frequently detected onconeural anti-
bodies in PCD patients are Yo antibodies.3 Yo reactivity with
cerebellar degeneration-related (CDR) proteins present in
Purkinje cells is associated with Purkinje cell death4 and severe
cerebellar degeneration.5
Yo antibodies react with 2 proteins, CDR2 (RefSeq
NP_001793.1) and CDR2-like (CDR2L; RefSeq NP_
055418.2), that have 45% sequence identity.6 CDR2 has
previously been considered as the main Yo antigen.6–9 This
assumption is based in part on the finding that only the CDR2
gene is expressed in tumors obtained from PCD patients.6
However, recent studies have demonstrated that both
CDR2 and CDR2L are widely expressed in normal as
well as in malignant tissues10,11 and that the CDR2L
protein, but not CDR2, is highly expressed in PCD
tumors.12 Furthermore, CDR2L protein deposits are
detected in germinal centers of all Yo-mediated PCD
tumors with tertiary lymphoid structures,12 suggesting
an ongoing local immune response against CDR2L. In line
with this, we have shown that preabsorption with CDR2L
abolishes Yo antibody staining of human Purkinje cells
completely, whereas preabsorption with CDR2 does not.13
To determine which onconeural antigen is the major
target of Yo antibodies, we studied the reactivity of Yo anti-
bodies toward both native and recombinant CDR2 and
CDR2L proteins. Our findings show that Yo antibodies react
only to native CDR2L, and not to CDR2, suggesting that
CDR2L is the major target of these antibodies in vivo.
Materials and Methods
Patient Samples
Five sex- and age-matched cerebrospinal fluid (CSF)/serum patient
samples with Yo antibodies (PCD patients) and 5 without Yo anti-
bodies (controls) were obtained from the Neurological Research
Laboratory, Haukeland University Hospital (Regional Committees
for Medical and Health Research Ethics (REK), #2013/1480).10
Cerebellar Tissue
Cerebellar sections were cut from fresh frozen normal human tis-
sue (REK, #2013/1503) or paraformaldehyde (PFA)-perfused rat
brains (The Norwegian regulation of the use of animals in
research, #20157494) that required additional heat-induced epi-
tope retrieval prior to immunostaining.14
Cell Cultures
The OvCar3 (American Type Culture Collection [ATCC], #HTB-
161) and the HepG2 (ATCC, #HB-8065) cancer cell lines were
maintained and subcultivated on poly-D-lysine–coated coverslips
(Neuvitro, Vancouver, WA; #GG-18-1.5-pdl) according to the
manufacturer’s protocol. Cells were washed (2 × 0.1M phosphate-
buffered saline [PBS]), fixed (15 minutes, 4% PFA-PBS; Thermo
Fisher Scientific, Waltham, MA; #28908), and quenched (5 minutes,
50mM NH4Cl; Sigma-Aldrich, St Louis, MO; #254134) prior to
immunostaining.
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Immunochemistry
Cancer cells and cerebellar sections were permeabilized (5 minutes,
0.5% Triton X-100-PBS; Sigma-Aldrich, #11332481001), washed
(3 × 15 minutes, 0.5% gelatin-PBS; Sigma-Aldrich, #G7041),
blocked (30 minutes, 10% SEABLOCK; Thermo Fisher, #37527),
incubated with primary antibodies (overnight, 4!C), washed,
incubated with secondary antibodies (2 hours, room temperature),
and mounted (ProLong Diamond with DAPI; Thermo Fisher Sci-
entific, #P36962). Antibodies consisted of rabbit anti-CDR2
(AA270-392; Sigma-Aldrich, #HPA018151; cerebellar sections and
HepG2 cells), mouse anti-CDR2 (full-length; LSBio, Seattle, WA;
#C181958; OvCar3 cells), rabbit anti-CDR2L (AA116-465; Pro-
tein Technology,Wuhan, Hubei, P.R.C #14563-1-AP), antihuman
Alexa Fluor 488/594 (Thermo Fisher Scientific, #A-11013/#A-
11014), antirabbit Alexa Fluor 488/594 (Thermo Fisher Scientific,
#R37116/#R37117), antirabbit STAR635P (Sigma-Aldrich,
#53399-500UG), and antimouse Alexa Fluor 488/594 (Thermo
Fisher Scientific, #R37120/#R37121). A Leica (Wetzlar, Germany)
SP8 STED 3X confocal microscope equipped with a × 100 1.4
numerical aperture oil objective was used for imaging.
Immunoprecipitation
Following the Bio-Rad SureBeads immunoprecipitation protocol,
the proteins were immunoprecipitated from OvCar3 cell lysate by
using Protein G Magnetic Beads (Bio-Rad Laboratories, Hercules,
CA; #161-4023). Immunoprecipitated proteins were separated on
a 10% TGX gel (Bio-Rad, #456-1035) and transferred to a poly-
vinylidene difluoride (PVDF) membrane using the Trans-Blot
Turbo Transfer kit (Bio-Rad, #170-4274). Western blot analysis
was performed to detect the immunoprecipitated target proteins.
Antibodies consisted of rabbit anti-CDR2L, mouse anti-CDR2,
Yo-CSF, TidyBlot (Bio-Rad, #STAR209PA), and horseradish per-
oxidase antimouse IgG (Dako, Carpinteria, CA; #P0260).
Fluorescent Immunoblotting
The cerebellar and cancer cell lysates were obtained using a Total
Protein Extraction Kit (Millipore, Billerica, MA; #2140). Proteins
were separated on a 10% TGX gel and transferred to a low-
autofluorescence PVDF membrane. Antibodies consisted of rabbit
anti-CDR2L, rabbit anti-CDR2, Yo-CSF, antirabbit Alexa Fluor
488, and antihuman Alexa Fluor 647 (Thermo Fisher Scientific,
#A-21445). G:Box (Syngene, Frederick, MA) was employed for
visualization.
Recombinant DNA and Transfection
Full-length CDR2 (OriGene Technologies, Rockville, MD;
#RG204900) and CDR2L (OriGene Technologies, #RC206909)
were ligated into a pCMV6-AC-GFP vector (OriGene Technologies,
FIGURE 1: Yo antibodies bind to CDR2L, but not CDR2, in
cerebellar Purkinje cells. Scale bars = 10μm. (A) Sections of fresh
frozen human cerebellum. Upper row: Section stained with Yo
(cerebrospinal fluid [CSF]; green) and anti-CDR2L (red); the
antibodies colocalize in the cytoplasm (seen as yellow in the
merge image). Lower row: Section stained with Yo (CSF; green)
and anti-CDR2 (red); no colocalization is seen between Yo and
CDR2. (B) Sections of paraformaldehyde (PFA)-perfused rat
cerebellum. Upper row: Section stained with Yo (CSF; green) and
anti-CDR2L (red); CDR2L colocalize with Yo. Lower row:
Section stained with Yo (CSF; green) anti-CDR2 (red); no
colocalization is seen. (C) Sections of PFA-perfused rat cerebellum.
Upper row: Section stained with Yo (serum; green) and anti-
CDR2L (red); Yo and CDR2L colocalize in the Purkinje cells
(outlined) as well as in the stellate and basket cells (arrows). Lower
row: Section stained with Yo (serum; green) and anti-CDR2 (red);
no colocalization is seen between Yo andCDR2. These images are
a z-stack merge, as not all stellate/basket cells were in the same
focal plane as the Purkinje cells; thus, the cytoplasmic staining
found over or under the nuclei may appear nuclear although it is
not (eg, the Yo serum staining is not nuclear). (D) Fluorescent
immunoblot of rat cerebellar lysate. Anti-CDR2L and Yo (CSF)
stain the same band at 55kDa; anti-CDR2 does not. Secondary
antibody controlswere negative.
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#PS100010). Following polymerase chain reaction, correct CDR2
and CDR2L vector sequences were confirmed using BioEdit v7.2.5.
One Shot TOP10 Escherichia coli (Life Technologies, Carlsbad, CA;
#C4040-10) were used for amplification, E.Z.N.A. Plasmid DNA
Kit (Omega Bio-Tek, Norcross, GA, #D6942) for purification, and
Lipofectamine 3000 (Thermo Fisher Scientific, #L3000008) for
transfection.
Results
CDR2L and Yo Staining Overlap
In sections of human and rat cerebellum, CDR2L showed a
cytoplasmic staining pattern in Purkinje cell somas that over-
lapped completely with the Yo antibody staining from both
CSF and serum (Fig 1). CDR2L and Yo also colocalized in
the stellate and basket cells. In contrast, CDR2 primarily
stained the nuclei of these neurons and gave no overlap with
the Yo antibodies. Under denaturing conditions, immuno-
fluorescence blots of rat cerebellar lysate showed that
CDR2L and Yo were recognized at 55kDa, whereas CDR2
was only visible at 62kDa.
CDR2L and Yo Colocalize in Ovarian Cancer Cells
In OvCar3 cells, which express both CDR2 and CDR2L
endogenously, we found that CDR2L and Yo colocalized
in the cytoplasm, whereas CDR2 showed no colocalization
with Yo (Fig 2A). The coreactivity of the CDR2L and Yo
FIGURE 2: Yo antibodies bind to CDR2L, but not CDR2, in
OvCar3 cells. Scale bars = 10μm. (A) Upper row: OvCar3 cells
stained with Yo (cerebrospinal fluid [CSF]; green) and anti-
CDR2L (red); Yo and CDR2L colocalize, giving the same
granular, cytoplasmic staining pattern (seen as yellow in the
merge image). Lower row: OvCar3 cells stained with Yo (CSF;
green) and anti-CDR2 (red); Yo does not colocalize with CDR2.
(B) Fluorescent immunoblot (IB) of OvCar3 lysate. Anti-CDR2L
and Yo (CSF) stain the same 55kDa band; anti-CDR2 does not.
Secondary antibody controls were negative. (C) Immunoblot of
proteins immunoprecipitated (IP) from the OvCar3 lysate by
Yo (CSF) or CDR2L. The protein precipitated by Yo antibodies
was recognized by the CDR2L antibody on Western blot (i) and
vice versa (ii); no relationship was observed between Yo or
CDR2L and CDR2.
FIGURE 3: HepG2 cells, with a high endogenous level of CDR2,
are not stained by Yo antibodies. However, Yo antibodies
are able to bind recombinant CDR2. Scale bars = 10μm.
(A) Untransfected HepG2 cells (first row) and HepG2 cells
transfected with a vector expressing recombinant CDR2L-
GFP (second and third row; green) were incubated with Yo
(cerebrospinal fluid [CSF]; red), anti-CDR2L (first and second row;
magenta), and anti-CDR2 (third row; magenta). Nuclei were
stained with DAPI. Only upon expression of recombinant CDR2L
was Yo and CDR2L antibody staining observed. The CDR2
antibody did not bind the recombinant CDR2L protein.
(B) Untransfected HepG2 cells (first row) and HepG2 cells
transfected with a vector expressing CDR2-GFP (second and
third row; green) were incubated with Yo (CSF; red), anti-CDR2
(first and second row; magenta), and anti-CDR2L (third row;
magenta). Native CDR2 is present in untransfected HepG2 cells,
but no Yo staining was found.When recombinant CDR2-GFPwas
present, both the Yo and CDR2L antibodywere able to bind.
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antibodies was confirmed by both fluorescent Western blot-
ting and immunoprecipitation (see Fig 2B, C).
Yo Antibodies Detect Recombinant CDR2 and
CDR2L
Yo and CDR2L staining was absent in untransfected HepG2
cells, whereas CDR2 was present in the nuclei of these cells
(Fig 3). In HepG2 cells transfected with recombinant CDR2
or CDR2L linked to green fluorescent protein (CDR2-GFP
and CDR2L-GFP), however, Yo antibodies colocalized with
both CDR2L-GFP and CDR2-GFP. Similar results were
obtained for all PCD samples tested.
Discussion
We demonstrate that Yo antibodies in the CSF and serum
of PCD patients consistently react with CDR2L in human
FIGURE 4: Proposed hypothesis of how Yo antibodies are able to bind both recombinant CDR2 and CDR2L, but only CDR2L under
native conditions. (A) Illustration of the initial, polyclonal response of Yo antibodies toward CDR2L in the tumors of paraneoplastic
cerebellar degeneration patients. (B) A tumor cell with the polyclonal Yo antibodies targeting the CDR2L protein; CDR2 is
unaffected, as the epitope that is common to CDR2L (blue) is hidden by post-translational modifications or a partnering molecule
(white fold covering the blue epitope). (C) The Yo antibodies also bind to CDR2L in cerebellar Purkinje cells; however, they do not
bind CDR2, as the common epitope (blue) is hidden here as well (by modifications or partnering molecules; white fold). (D) When
patient sera or cerebrospinal fluid is applied to a line blot with recombinant CDR2 attached, binding of the common epitope (blue)
is possible, as it is not hidden by post-translational modifications or partnering molecules in the recombinant version.
4 Volume 00, No. 0
ANNALS of Neurology
and rat brain tissue as well as in cultured cancer cells.
Despite sequence homology between CDR2 and CDR2L,
Yo antibodies did not cross-react with endogenously
expressed CDR2. These findings were confirmed by using
HepG2 cells that express CDR2 endogenously, but not
CDR2L; Yo antibodies were not able to bind the endoge-
nous CDR2 in these cells either. We therefore conclude
that CDR2L is the major antigen of Yo antibodies under
native conditions. This result indicates that previous
research on Yo-mediated PCD has focused on a protein
that is not the major antigenic target of Yo antibodies.
CDR2L and Yo antibodies gave a granular, cytoplas-
mic staining pattern that colocalized in both human and
rat Purkinje cells, as well as in stellate and basket cells. In
contrast, CDR2 reactivity primarily occurred in the nuclei
of these neuronal cells, where Yo antibody staining was
absent. In the human cancer cell lines OvCar3 and HepG2,
we found strong staining of CDR2 in the nuclei, as well as
some cytoplasmic staining. Similar CDR2 staining has also
been found in other cancer cell lines and tissues.15
We found that none of our PCD patient samples
cross-reacted with endogenous CDR2. Thus, CDR2L-
exclusive epitopes appear to be the major targets of Yo anti-
bodies under native conditions. Furthermore, we observed
competitive binding between the CDR2L and the Yo anti-
bodies, whereas the CDR2 antibody staining was not
affected by high Yo antibody concentrations (data not
shown). This is in line with our previous results showing that
the reactivity of Yo antibodies in the Purkinje cells disappears
completely when preabsorbed with recombinant CDR2L
protein, but only partially with recombinant CDR2.13
In routine clinical testing for onconeural antibodies,
line blots and cell-based assays use recombinant CDR2 as
the antigen target for Yo antibodies (Euroimmun, www.
euroimmun.com; ravo Diagnostika, www.ravo.de). Because
we did not find any reactivity of Yo antibodies toward
native CDR2, we investigated this further by transfecting
HepG2 cells with CDR2 and CDR2L linked to green fluo-
rescent protein. Our results showed that Yo antibodies did
bind recombinant CDR2, meaning that the protein can
still be used for clinical diagnostic purposes. However, line
blot and cell-based assays using CDR2L may be more sensi-
tive for detecting Yo antibodies.
Whereas Yo antibodies are able to bind recombinant
CDR2, they appear unable to access this epitope on endoge-
nous CDR2, likely because it is hidden by post-translational
modifications or by partnering molecules (Fig 4). A recent
study did not find any common linear epitopes detected by
Yo antibodies for CDR2 and CDR2L.16 This suggests that
any common epitope is likely conformational, a feature that
can be elucidated once the 3-dimensional structures of these
proteins are established.
Our present results strengthen the hypothesis that
CDR2L is the major target of Yo antibodies. This is in line
with the recent findings that CDR2L expression was detected
in all samples of ovarian cancers from PCD patients, whereas
CDR2 was only weakly expressed in 40% of the tumors.12
Furthermore, CDR2L deposits were found in germinal cen-
ters of all Yo-mediated PCD tumors with tertiary lymphoid
structures, suggesting a humoral immune response against
CDR2L.12 Thus, Yo antibodies targeting CDR2L in tumor
cells, with binding of CDR2L in Purkinje cells as an unfortu-
nate side effect, likely contributes to the development of
PCD. CDR2L should therefore be included in future research
into the pathogenesis of Yo-mediated PCD.
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Abstract
Objective: Identify the subcellular location and potential binding partners of
two cerebellar degeneration-related proteins, CDR2L and CDR2, associated with
anti-Yo-mediated paraneoplastic cerebellar degeneration. Methods: Cancer cells,
rat Purkinje neuron cultures, and human cerebellar sections were exposed to
cerebrospinal fluid and serum from patients with paraneoplastic cerebellar
degeneration with Yo antibodies and with several antibodies against CDR2L and
CDR2. We used mass spectrometry-based proteomics, super-resolution micro-
scopy, proximity ligation assay, and co-immunoprecipitation to verify the anti-
bodies and to identify potential binding partners. Results: We confirmed the
CDR2L specificity of Yo antibodies by mass spectrometry-based proteomics and
found that CDR2L localized to the cytoplasm and CDR2 to the nucleus. CDR2L
co-localized with the 40S ribosomal protein S6, while CDR2 co-localized with
the nuclear speckle proteins SON, eukaryotic initiation factor 4A-III, and serine/
arginine-rich splicing factor 2. Interpretation: We showed that Yo antibodies
specifically bind to CDR2L in Purkinje neurons of PCD patients where they
potentially interfere with the function of the ribosomal machinery resulting in
disrupted mRNA translation and/or protein synthesis. Our findings demonstrat-
ing that CDR2L interacts with ribosomal proteins and CDR2 with nuclear
speckle proteins is an important step toward understanding PCD pathogenesis.
Introduction
Paraneoplastic neurological syndromes are rare autoim-
mune-mediated diseases1,2 characterized by the production
of antibodies that target antigens expressed both by the
tumor and endogenously in the central nervous system.3,4
One of the most common forms of paraneoplastic neuro-
logical syndromes is paraneoplastic cerebellar degeneration
(PCD).5 In patients with PCD and breast or ovarian cancer,
the dominant onconeural antibody, anti-Yo, is detected in
both serum and cerebrospinal fluid (CSF).6 Anti-Yo anti-
bodies are directed against two proteins, cerebellar degener-
ation-related protein 2 (CDR2) and CDR2-like (CDR2L),
which are endogenously expressed in Purkinje neurons of
the cerebellum.7 The interaction between anti-Yo and CDR
proteins is thought to mediate Purkinje neuron dysfunction
and death.5 A two-step process has been proposed, with the
internalization of Yo antibodies as the primary event,
ª 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
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followed by the subsequent activation of cytotoxic T cells.8,9
However, it has also been demonstrated that Yo antibodies
can induce Purkinje neuron death in the absence of T lym-
phocytes.8,10
Previously we showed that CDR2L is the major Yo
antibody target in PCD.7 However, we cannot exclude a
functional role for CDR2 in anti-Yo-mediated PCD
pathogenesis. These proteins display a high degree of
homology with approximately 45% sequence identity,11,12
and both are widely expressed in normal as well as malig-
nant tissues.3,13 Ovarian malignancy is the most frequent
cancer type found in Yo-mediated PCD, and both CDR2L
and CDR2 are highly expressed in this type of cancer.3,14
Earlier studies have suggested that CDR2L and CDR2 are
cytoplasmic proteins.3,13 However, detailed subcellular
localization using antigen-specific antibodies has not been
performed. Current knowledge concerning the biologic
function of CDR2L is limited. CDR2 has leucine zipper and
zinc-finger DNA binding domains, characteristic of tran-
scriptional regulatory proteins11,15,16 and occurrence of
these domains in the predicted open reading frame suggests
that CDR2 has a role in regulating gene expression.11,17
CDR2 interacts with the serine/threonine protein kinase
PKN and cell cycle-related proteins MRG15 and MRGX; all
involved in signal transduction or gene transcription.15,18,19
In this study, we examined the subcellular locations of
CDR2L and CDR2 and their protein-protein interactions.
Our findings suggest that CDR2L and CDR2 have differ-
ent roles: CDR2L interacts with cytosolic ribosomes and
appears to function in protein synthesis, while CDR2
associates with nuclear speckle proteins and appears to be
involved in mRNA maturation.
Materials and Methods
Patient samples
Five sex- and age-matched CSF samples from patients
with Yo antibodies (PCD patients) and five without Yo
antibodies and no neurological disease or underlying can-
cer (negative controls) were obtained from the Neurologi-
cal Research Laboratory, Haukeland University Hospital
(Regional Committees for Medical and Health Research
Ethics, 2013/1480).
Cell culture
OvCar3 (American Type Culture Collection (ATCC),
#HTB-161) and HepG2 (ATCC, #HB-8065) cancer cell
lines were maintained and subcultivated on poly-D-lysine-
coated coverslips (Neuvitro, #GG-18-1.5-pdl) according to
the manufacturer’s protocol. Cells were washed twice with
0.1 M phosphate-buffered saline (PBS), fixed (15 min, 4%
paraformaldehyde in PBS, Thermo Fisher Scientific,
#28908), and quenched (5 min, 50 mmol/L NH4Cl, Sigma-
Aldrich, #254134) prior to immunostaining.
Cerebellar tissue preparation
Cerebellar sections were cut from fresh frozen normal
human tissue (REK, #2013/1503). Heat-induced epitope
retrieval was performed prior to immunostaining.
Rat Purkinje neuron cultures
All procedures were performed according to the National
Institutes of Health Guidelines for the Care and Use of
Laboratory Animals Norway (FOTS 20135149/20157494/
20170001). Embryonic day 18 Wistar Hannover GLAST
rat pups were used for neuronal culture preparation. The
protocol has recently been described.20
Immunochemistry
Fixed OvCar3 cells and cerebellar sections were permeabi-
lized in 0.5% Triton X-100-PBS (Sigma-Aldrich,
#11332481001) for 5 min, washed in 0.5% gelatin-PBS
(Sigma-Aldrich, #G7041) three times with 15 min each
wash, blocked in 10% SEABLOCK (Thermo Fisher Scien-
tific, #37527) in PBS for 30 min, and incubated with pri-
mary antibodies overnight at 4 °C. Following incubations,
cells and sections were washed in gelatin-PBS, incubated
with secondary antibodies for 2 h at room temperature,
and mounted using ProLong Diamond with DAPI
(Thermo Fisher Scientific, #P36962). The following anti-
bodies were used: rabbit anti-CDR2 (Sigma-Aldrich,
#HPA018151), rabbit anti-CDR2L (Protein Technology,
#14563-1-AP), mouse anti-rpS6 (Cell Signaling, #2317/
Santa Cruz #sc-74459), mouse anti-SON (Santa Cruz,
#sc398508), mouse anti-eIF4A3 (Santa Cruz, #sc-365549),
mouse anti-SRSF2 (Abcam, #ab11826), Alexa Fluor 488/
594-labeled goat anti-human (Thermo Fisher Scientific,
#A-11013/#A11014), Alexa Fluor 488/594-labeled goat
anti-rabbit (Thermo Fisher Scientific, #R37116/#R37117),
rabbit anti-STAR635P (Sigma-Aldrich, #53399-500UG),
and Alexa Fluor 488/594-labeled goat anti-mouse (Thermo
Fisher Scientific, #R37120/#R37121).
Super-resolution microscopy
A Leica TCS SP8 Stimulated Emission Depletion (STED) 3X
confocal microscope equipped with a 100x oil objective with
a numerical aperture of 1.4 was used for imaging. The output
of the excitation laser (up to 1.5 mW per line; pulsed) was
kept between 1% and 20% and the STED laser (775 nm; up
to 1.5 W) between 20% and 30%. Gating (between 1 and
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6 ns) was applied for all channels as well as a minimum of
three intensity averages. The lateral resolution was consis-
tently measured to be between 40 and 50 nm.
Immunoprecipitation
OvCar3 and HepG2 cells were lysed in RIPA lysis buffer
(Bioscience #786-490) containing protease inhibitor cock-
tail (Sigma-Aldrich #11873580001), 1 mmol/L phenyl-
methylsulfonyl fluoride (PMSF, Sigma-Aldrich #P7626),
1 mmol/L sodium fluoride (NaF, Sigma-Aldrich #S6776),
and 1 mmol/L sodium orthovanadate (Na3VO4, Sigma-
Aldrich #450243). The lysate was centrifuged (22,000g,
4°C, 15 min) and the supernatant was collected.
Following the Bio-Rad SureBeads immunoprecipitation
protocol, the proteins were immunoprecipitated from
OvCar3 and HepG2 cell lysates using Protein G Magnetic
Beads (Dynabeads, Thermo Fischer Scientific, #1004D).
Immunoprecipitated proteins were separated on a 10%
TGX gel (Bio-Rad, #456-1035) and transferred to a
polyvinylidene difluoride (PVDF) membrane using the
Trans-Blot Turbo Transfer kit (Bio-Rad, #170-4274).
Western blot analysis was performed to detect proteins of
interest using the following primary antibodies: rabbit
anti-CDR2L (Proteintech, #14563-1-AP), mouse anti-rpS6
(Santa Cruz #sc-74459), rabbit anti-CDR2 (Sigma-
Aldrich, #018151), mouse anti-CDR2 (Santa Cruz,
#sc100320) mouse anti-SON, mouse and rabbit anti-
eIF4A3 (Abcam, #ab32485). The secondary antibodies
used were TidyBlot (Bio-Rad, #STAR209PA) and horse-
radish peroxidase anti-mouse IgG and anti-rabbit IgG
(Dako, #P0260 and #P0217). A negative control consist-
ing of beads and cancer cell lysate was also included.
Proximity ligation assay
The proximity ligation assay was performed using the
commercially available Duolink kit from Sigma-Aldrich
(#DUO92101). Fixed OvCar3 cells were permeabilized for
5 min using 0.5% Triton X-100 diluted in PBS and
blocked with 10% SEABLOCK in PBS. Primary antibodies
against Hsp60 (EnCor Biotechnology, #CPCA-HSP60),
CDR2 (Sigma-Aldrich, #018151), CDR2L (Proteintech,
#14563-1-AP), SON, and SRSF2 were applied for 1 h
(1:100 in blocking solution), followed by 3x 5-minute
washes with Wash Buffer A supplied with the kit. Probes
(+ and !) were diluted in blocking solution (1:5) and
added to the cells for 1 h (37 °C). The cells were washed
3x for 5 min each with Wash Buffer A and incubated
with ligation buffer (1:5) and ligase enzyme (1:40) for
30 min (37°C). After 2x 5-minute washes with Wash Buf-
fer A amplification buffer (1:5) and the polymerase
enzyme (1:80) were diluted in distilled water and applied
to the cells for 100 min (37 °C, in the dark), followed by
three 10-minute washes with Wash Buffer B (supplied
with the kit). Prolong Diamond with DAPI was used to
mount the coverslips (overnight, 4 °C). Mounted cells
were stored at !20 °C.
Mass spectrometry-based proteomics
analysis
Proteins of interest were immunoprecipitated from
HepG2 or OvCar3 cell lysates using the antibodies listed
in Table 1. A negative control consisting of beads and
cancer cell lysate was also included. The samples were
loaded on a 10% TGX gel and run approximately 1 cm
into the resolving gel. Each lane was cut into cubes of
approximately 1 mm2 and hydrated in Milli-Q water
(20 min, room temperature). Detergents (i.e. sodium
dodecyl sulfate) and salts were removed by washing the
gel in 25 mmol/L ammonium bicarbonate (Sigma-
Aldrich, #09830-500G) and 50% acetonitrile (VWR,
#34967-2.5L). Cysteine reduction and alkylation were
accomplished with a 45-minute incubation in 10 mmol/L
dithiothreitol (Amersham Biosciences, #171318-02) at 56
Table 1. Antibody specificities determined by mass spectrometry analysis of CDR2L and CDR2 proteins immunoprecipitated from OvCar3 and
HepG2 cell lysates.
Target Source/Supplier Cat. no. AA seq. Cell line #Peptides Interaction
Yo Yo positive CSF OvCar3 54 CDR2L
Yo Yo positive CSF HepG2 - -
CDR2L Sigma- Aldrich HPA022015 395-464 OvCar3 56 CDR2L
CDR2L Proteintech 14563-1-AP 116-465 OvCar3 68 CDR2L
CDR2L Proteintech 66791-1-Ig 116-465 OvCar3 69 CDR2L
CDR2 Sigma-Aldrich HPA018151 270-392 HepG2 49 CDR2
CDR2 Sigma-Aldrich HPA023870 112-234 HepG2 41 CDR2
CDR2 Santa Cruz Sc-100320 296-405 HepG2 57 CDR2
CDR2 LS Bio C181958 Full length HepG2 51 CDR2
AA seq., amino acid sequence.
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°C followed by a 30-minute incubation in 55 mmol/L
iodoacetamide (VWR, #M216-30G) at room temperature
in the dark. After washing in 25 mmol/L ammonium
bicarbonate and 50% acetonitrile, dried gel pieces were
hydrated on ice for 20 min with a minimum volume of
6 ng/µL trypsin (sequencing-grade modified, Promega,
#V511A) in digestion buffer (20 mmol/L ammonium
bicarbonate, 1 mmol/L calcium chloride (Sigma-Aldrich,
#C7902)), then covered with digestion buffer and incu-
bated for 16 h at 37°C. Trypsin activity was quenched by
acidification with trifluoracetic acid (VWR,
#1.08218.0050), and samples were desalted using StageTip
C18 columns (Empore disk-C18, Agilent Life Sciences,
#12145004) and the eluted peptides were dried and dis-
solved in 2% acetonitrile, 1% formic acid (VWR,
#84865.260).21
About 0.5 µg tryptic peptides were loaded onto an
Ultimate 3000 RSLC system (Thermo Fisher Scientific)
connected online to a Q-Exactive HF mass spectrometer
(Thermo Fisher Scientific) equipped with EASY-spray
nano-electrospray ion source (Thermo Fisher Scientific).
All samples were loaded and desalted on a pre-column
(Acclaim PepMap 100, 2 cm x 75 µm ID nanoViper col-
umn, packed with 3 µm C18 beads) at a flow rate of 5
µL/min with 0.1% trifluoracetic acid. Peptides were sepa-
rated during a biphasic acetonitrile gradient (flow rate of
200 nL/minute) on a 50-cm analytical column (PepMap
RSLC, 50 cm x 75 µm ID EASY-spray column, packed
with 2 µm C18 beads). Solvent A and B were 0.1% for-
mic acid in water and 100% acetonitrile, respectively. The
gradient composition was 5% B during trapping (5 min)
followed by 5–7% B over 0.5 min, 7–22% B for the next
59.5 min, 22–35% B over 22 min, and 35–80% B over
5 min. Elution of very hydrophobic peptides and condi-
tioning of the column was performed during a 10-minute
isocratic elution with 80% B and 15 min of isocratic con-
ditioning with 5% B, respectively.
Charged peptides were analyzed by the Q-Exactive HF,
operating in the data-dependent acquisition mode to
automatically switch between full-scan MS and MS/MS
acquisition. Mass spectra were acquired in the scan range
375–1500 m/z with a resolution of 60,000 at m/z 200
after an accumulation of 3,000,000 charges (maximum
trap time set at 50 ms in the C-trap). The 12 peptides
with the most intense signals above an intensity thresh-
old of 50,000 counts and with charge states of 2 to 6
were sequentially isolated and accumulated to 100,000
charges (maximum trap time set at 110 ms) to a target
value of 1 9 105 or a maximum trap time of 110 ms in
the C-trap with isolation width maintained at 1.6 m/z
(offset of 0.3 m/z) before fragmentation in the higher
energy collision dissociation cell. Fragmentation was per-
formed with a normalized collision energy of 32%, and
fragments were detected in the Q-Exactive at a resolution
of 60,000 at m/z 200 with first mass fixed at m/z 110.
One MS/MS spectrum of a precursor mass was allowed
before dynamic exclusion for 30 seconds with “exclude
isotopes” on. Accurate mass measurements in MS mode
were accomplished by enabling the lock-mass internal
calibration of the polydimethylcyclosiloxane ions gener-
ated in the electrospray process from ambient air (m/z
445.12003).22
Database searching and criteria for protein
identification
Tandem mass spectra data were extracted with Proteome
Discoverer (version 2.3.0.523, Thermo Fisher Scientific)
and were searched against human, reviewed protein
sequences (SwissprotKB database, release 08-2018) with
Sequest HT and MS Amanda search engines. The follow-
ing search criteria were used: carbamidomethylation of
cysteine (fixed modification), oxidation of methionine
and acetyl of the protein N-terminus (variable modifica-
tions), a maximum of two missed trypsin cleavages, 0.02-
Da fragment ion mass tolerance, and 10-ppm precursor
ion tolerance. Search results from PD were loaded into
Scaffold 4 (version 4.9.0, Proteome Software Inc.), and all
spectra were searched with the X! Tandem search engine
against identified proteins to identify nonspecific trypsin
cleavages.
Peptide and protein identifications were filtered to
achieve a false discovery rate < 1.0% (based on searching
the reversed human database). Grouping of proteins shar-
ing identical peptides was enabled. In order to evaluate
the likelihood of the predicted interactions, the following
criteria were established: (1) nonspecific bindings were
removed based on the negative control (without primary
antibodies); (2) the number of recognized peptides was
set to at least two; (3) proteins that were identified by
more than one of the antibodies to CDR2L or CDR2 were
considered as more likely partners; (4) the likelihood of
Figure 1. Protein-protein interaction networks visualized by STRING. (A) CDR2L was predicted to interact with ribosomal proteins (rpS6, red box).
The nodes indicate proteins, and the edges represent protein-protein associations. (B) Protein-protein interaction network of nuclear speckles
proteins, SON, eIF4A3, and SRSF2, predicted to interact with CDR2. eIF4A3 (red) directly interacts with SON (light green) and SRSF2 (blue). (C)
eIF4A3 (yellow) interacts with rpS6 (blue), indicated by colored edges. Predicted binding partners, CDR2L (green) and CDR2 (red), are manually
gated (black, dotted lines). Color-coded edges; light blue: curated databases, dark blue: gene co-occurrence, pink: experimentally determined,
green: text mining. Interactions with a medium score of 0.400 or more are shown.
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interaction was evaluated based on the predicted cellular
location of each protein of interest. Protein-protein inter-
actions were analyzed using the STRING database.
STRING implements all publicly available sources of
known and predicted protein-protein associations,




To evaluate antibody specificity, we immunoprecipitated
CDR2L and CDR2 from cancer cell lysates and analyzed
the precipitates using mass spectrometry-based
Figure 2. CDR2L co-localizes with ribosomes and CDR2 with nuclear speckles in OvCar3 cells as shown using proximity ligation assay. (A) Upper
row: Co-localization of anti-CDR2L (green) and ribosomes (rpS6; red) in the cytoplasm (yellow; merged image). Lower row: Co-localization of
anti-CDR2 (green) and nuclear speckles (SRSF2; red) in the nucleus (yellow; merged image). (B) Upper row: Positive Duolink (green) between
CDR2L and ribosomes (rpS6) in the cytoplasm (hsp60 in magenta was used to show the extent of the cell cytoplasm; merged image). Lower row:
Positive Duolink (green) between CDR2 and nuclear speckle marker (SRSF2) in the nuclei; no co-localization was observed with cytoplasmic
marker hsp60 (magenta; merged image). DAPI was used as a marker for the nuclei (blue). Scare bars = 10 µm.
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proteomics with the antibodies listed in Table 1. We
found that the commercial antibodies raised against
CDR2L and CDR2 were specific and recognized the
expected antigens. Also, we confirmed our previous data
showing that CDR2L is the major Yo antibody target.
Analysis of lysates of OvCar3 cells, which expresses both
CDR2L and CDR2, immunoprecipitated with Yo antibod-
ies bound to magnetic beads showed that CDR2L, but
not CDR2, was recognized by Yo antibodies. In similar
experiments performed with a cell line that only expresses
CDR2, HepG2 cells, Yo antibody did not precipitate
CDR2.
CDR2L and CDR2 interaction partners
identified by mass spectrometry analysis
Potential protein interaction partners were identified
using mass spectrometry analysis of proteins immuno-
precipitated with anti-CDR2L and anti-CDR2 antibodies
from cancer cell lysates. Initially, several hundred hits
were detected, and four criteria were established to
determine the likelihood of the predicted interactions.
Thereafter, we used the STRING database to evaluate
the connectivity of the proteins that met our criteria.
CDR2L was predicted to interact with 50 ribosomal
proteins that were tightly connected (Fig. 1A). Of these
50 ribosomal proteins, 20 belong to the 40S subunit,
and 30 belong to the 60S subunit. Proteins known to
associate with nuclear speckles, eukaryotic initiation fac-
tor eIF4A3, SON, and the serine/arginine-rich splicing
factor SRSF2, were identified as potential interaction
partners of CDR2. According to the STRING analysis
eIF4A3 interacts with SON and SRSF2 (Fig. 1B), as well
as with the 40S ribosomal subunit factor rpS6
(Fig. 1C).
CDR2L Co-localizes with ribosomal proteins
and CDR2 with nuclear speckle proteins in
ovarian cancer cells
We used immunolabeling and proximity ligation assay to
investigate the subcellular localization of CDR2L and CDR2.
In OvCar3 cells, which express both CDR2L and CDR2, we
found that CDR2L co-localizes with rpS6, whereas CDR2
co-localizes with nuclear speckle proteins SON, eIF4A3, and
SRSF2 (Fig. 2A). These results were confirmed by proximity
ligation assay in OvCar3 cells (Fig. 2B).
Co-Immunoprecipitation of CDR2L and CDR2
from OvCar3 cells confirms protein-protein
interactions with ribosomal and nuclear
speckle proteins
To analyze whether CDR2L directly interacts with rpS6,
we performed co-immunoprecipitation assays from
OvCar3 cell lysates. CDR2L specifically co-immunoprecip-
itated with rpS6, indicating that endogenous CDR2L
forms a complex with rpS6 in cancer cells (Fig. 3A). Fur-
thermore, we found that SON and eIF4A3 co-immuno-
precipitated with CDR2 from HepG2 cells, thus
indicating a strong and stable interaction between these
proteins and CDR2 (Fig. 3B).
Co-localizations of CDR2L with ribosomal
proteins and of CDR2 with nuclear speckle
proteins occurs in Purkinje neurons in
Human cerebellum sections and in Purkinje
neuron cultures
In human cerebellum sections, CDR2L and Yo antibodies
stained the cytoplasm in regions that overlapped with
Figure 3. CDR2L co-immunoprecipitates with ribosomal protein rpS6, whereas CDR2 co-immunoprecipitates with nuclear speckle proteins SON
and eIF4A3 in cancer cell lysates. (A) Immunoblot demonstrating the co-immunoprecipitation of CDR2L and rpS6 from OvCar3 cell lysates. (B)
Immunoblot demonstrating the co-immunoprecipitation of CDR2, SON, and eIF4A3 from HepG2 cell lysates. Input = cancer cell lysates (OvCar3
or HepG2). Beads + lysate = samples that were not treated with primary antibody, and served as negative controls.
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regions stained for the ribosomal marker rpS6, whereas
CDR2 showed nuclear staining that overlapped with
nuclear speckle markers (eIF4A3, SON, and SRSF2;
Fig. 4A). These results were replicated in cultured rat
Purkinje neurons (Fig. 4B).
Discussion
The pathogenesis of Yo-mediated PCD remains incom-
pletely understood, but it has been postulated that the
Purkinje neuron loss is due to auto-reactive T cells and a
direct damaging effect of Yo antibodies.3,4,6,25 We demon-
strated previously that CDR2L, not CDR2, is the major
target of the Yo antibody7: Yo antibodies bind both
endogenous and recombinant CDR2L, but only recombi-
nant CDR2, not the native form. In this study, we con-
firmed the CDR2L specificity of Yo antibodies by mass
spectrometry-based proteomics and showed that while
CDR2L and CDR2 have differing localizations, it is possi-
ble to link their putative roles to ribosomal function.
The biological functions and precise subcellular local-
ization of both CDR2L and CDR2 have been unresolved
questions. Analysis of PCD patient sera has shown that
Yo antibodies localize to the cytoplasm and associate with
both membrane-bound and free ribosomes.26,27 In these
studies, the Yo antigen is referred to as “CDR2.” How-
ever, based on our recent findings, we are confident that
the main Yo antigen is indeed CDR2L. Here, we used
available antibodies against CDR2L and CDR2, as well as
anti-Yo, to characterize the cellular localization of these
proteins and their potential binding partners.
Immunolabeling cells with commercially available anti-
CDR2 antibodies result in various expression patterns,
localizing CDR2 to both the cytoplasm and the
nucleus.7,13 Therefore, we first evaluated the specificity of
the available CDR2L and CDR2 antibodies produced to
recognize the full-length protein or shorter sequences.
Immunoprecipitation followed by mass spectrometry
analysis confirmed antibody specificity. The previously
reported inconsistent results for CDR2 may either stem
from the antibody recognition of one of the four CDR2
isoforms (www.uniprot.org) or from the translocation of
CDR2 between the cytoplasm and nucleus. Furthermore,
previous studies also identified PKN, MRG15, and MRGX
as CDR2 binding partners. Since these proteins function
both in the cytoplasm and nucleus, this raises the possi-
bility that CDR2 might facilitate the transport of these
proteins or translocate itself.15,18,19,28 In addition, no
CDR2L-CDR2 cross-talk was observed, which supports
our finding that there is no cross-talk between CDR2L
and CDR2 in their native forms. Furthermore, our
immunoprecipitation-mass spectrometry results showed
that Yo antibodies only precipitated CDR2L and not
CDR2 from cancer cells. This is in line with recent work,
which shows that Yo antibodies bind to the CDR2L
regions of least homology with CDR2.29
In addition to confirming antibody specificity, the mass
spectrometry analysis revealed potential interacting part-
ners for CDR2L and CDR2. A number of ribosomal pro-
teins, including rpS6, were identified as potential CDR2L
binding partners. The most prominent CDR2 binding
partners were three nuclear speckle proteins: SON,
eIF4A3, and SRSF2. Next, we used super-resolution
microscopy and proximity ligation assay to evaluate co-
localization within a 40-nm range in cancer cells and
Purkinje neurons. CDR2L was found to co-localize with
rpS6, whereas CDR2 co-localized with nuclear speckle
proteins eIF4A3, SON, and SRSF2. Co-immunoprecipita-
tion analyses established that CDR2L directly interacts
with rpS6 and that CDR2 directly interacts with eIF4A3
and SON.
Nuclear speckles are self-assembled organelles consist-
ing of around 200 proteins involved in pre-mRNA pro-
cessing including splicing, surveillance, and RNA
export.30 The speckles can vary in size and morphology
within a single cell, but have been shown to be non-ran-
dom organizations of proteins and RNAs stabilized by
favorable intermolecular interactions.30 SRSF2 and SON
localize to the core region of the speckle; both proteins
have domains enriched with arginine and serine repeats
that are crucial for speckle core formation.30,31 Both pro-
teins are also involved in mRNA splicing32,33 and interact
with the ATP-dependent RNA helicase eIF4A3.34 It has
been suggested that eIF4A3 may provide a link between
Figure 4. CDR2L and Yo co-localize with ribosomal proteins and CDR2 co-localizes with nuclear speckle proteins in cerebellar Purkinje neurons as
shown by super-resolution microscopy. (A) Upper row: Human cerebellar section stained with Yo-CSF (green) and anti-rpS6 (red); the proteins co-
localize in the cytoplasm (yellow; merged image). Middle row: Human cerebellar section stained with anti-CDR2L (green) and ribosomal marker
anti-rpS6 (red); the proteins co-localize in the cytoplasm (yellow; merged image). Lower row: Human cerebellar section stained with anti-CDR2
(green) and nuclear speckle marker anti-SRSF2 (red); the proteins co-localize in the nucleus. No co-localization was found with anti-Yo (magenta;
merged image). (B) Upper row: Rat Purkinje neuron cultures stained with anti-Yo (CSF; green) and rpS6 (ribosomes; red); co-localization was
observed in the cytoplasm (yellow; merged image). Middle row: Rat Purkinje neuron cultures stained with anti-CDR2L (green) and anti-rpS6 (red);
co-localization was observed in the cytoplasm (yellow; merge image). Lower row: Rat Purkinje neurons stained with anti-CDR2 (green), nuclear
speckle protein (red), and anti-Yo (magenta). CDR2 and the nuclear speckle protein co-localize in the cell nucleus (yellow; merged image),
whereas Yo does not. Scale bars = 10 µm.
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splicing and translation in the cytoplasm through its con-
nection to rpS634,35, which co-localizes with CDR2L.
Translation in eukaryotes relies on the assembly of the
small (40S) and the large (60S) ribosomal subunit into
the 80S ribosomes.36 Each subunit is composed of riboso-
mal proteins and RNAs that work together to catalyze
protein synthesis using mRNA as a template.37,38 Riboso-
mal proteins often undergo post-translational modifica-
tions and rps6, the identified CDR2L binding partner, is
regulated by phosphorylation.39,40 Five phosphorylation
sites have been identified and these phosphorylation
events could participate in regulating the translation of
specific subclasses of mRNA, synaptic plasticity and
behavior.41 Thus, rpS6 phosphorylation is often used to
track neuronal activity.40,41
Our findings linking CDR2 to nuclear speckles and
CDR2L to ribosomes allow us to speculate that these two
proteins may participate in a common pathway (Fig. 5).
First, we show that CDR2 interacts with eIF4A3 in the
nucleus. Second, eIF4A3, along with other initiation fac-
tors, facilitates mRNA binding to ribosomes.42 Further-
more, eIF4A3 and rpS6 have been shown to interact
based on affinity-capture mass spectrometry analysis.35
Third, we show that CDR2L interacts with the ribosomes
through rpS6. These findings place CDR2 and CDR2L in
the process of protein translation, one involved in mRNA
maturation and the other directly with the synthesis of
proteins.
Ensuring proper protein homeostasis is crucial to the
cell.36,38 We show that Yo antibodies specifically bind to
Figure 5. Hypothesis of CDR2L and CDR2 involvement in protein synthesis in Purkinje neurons. CDR2 localizes to the nucleus and directly
interacts with nuclear speckle protein eIF4A3. eIF4A3, in conjugation with other cytoplasmic initiation factors, facilitates mRNA binding to the 40S
ribosomal subunit. This event is important for mRNA maturation and translation, ultimately resulting in the synthesis of new proteins. CDR2L
interacts with ribosomal subunit protein rpS6; therefore, we propose that CDR2L and CDR2 are both involved in the process of protein synthesis.
Furthermore, Yo antibody (green) binding to CDR2L in Purkinje neurons of PCD patients may, therefore, interfere with the function of the
ribosomal machinery, resulting in disrupted mRNA translation and/or protein synthesis.
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CDR2L in Purkinje neurons of PCD patients where they
potentially interfere with the function of the ribosomal
machinery resulting in disrupted mRNA translation and/
or protein synthesis. Taken together, our findings that
CDR2L interacts with ribosomal proteins and CDR2 with
nuclear speckle proteins is an important step toward
understanding PCD pathogenesis. Future studies are
needed to track the subcellular events in real-time with
the aim of addressing the dynamic interaction between
the CDR2L and CDR2 molecules. This will be vital to
understand whether there is a functional relationship
between CDR2L and CDR2 in the Purkinje neuron deteri-
oration that occurs in PCD.
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Investigate the value of including cerebellar degeneration-related protein 2-like (CDR2L) as a
marker in commercial diagnostic tests for anti-Yo–associated paraneoplastic cerebellar de-
generation (PCD).
Methods
We included sera and CSF samples from 24 patients with suspected PCD (6 of whom had PCD
with underlying gynecologic or breast cancer), who were positive for Yo antibodies using the
commercially available, paraneoplastic neurologic syndromes (PNS) 14 Line Assay from Ravo
Diagnostika. The samples were further evaluated using the EUROLINE PNS 12 Ag Line Assay
and a cell-based assay (CBA) fromEuroimmun. For confirmation of positive lineblot results, we
used indirect immunofluorescence of rat cerebellar sections. We also tested all samples in 2
assays developed in-house: a CBA for CDR2L and a Western blot analysis using recombinant
cerebellar degeneration-related protein 2 (CDR2) and CDR2L proteins.
Results
In PNS 14 and PNS 12 Ag Line Assays, anti-CDR2 reactivity was observed for 24 (100%) and
20 (83%) of the 24 samples, respectively. Thirteen of 24 subjects (54%) were also positive using
the Euroimmun CBA. Rat cerebellar immunofluorescence was the best confirmatory test. In
our in-house CBA for CDR2L and Western blot for CDR2 and CDR2L, only the 6 patients
with confirmed PCD reacted with CDR2L.
Conclusions
Commercially available tests for Yo antibody detection have low specificity for PCD because
these assays use CDR2 as antigen. By adding a test for CDR2L, which is the major Yo antigen,
the accuracy of PCD diagnosis greatly improved.
Classification of Evidence
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Paraneoplastic neurologic syndromes (PNS) are rare,
immune-mediated diseases triggered by cancer that differ in
clinical features, prognosis, and associated onconeural
antibodies.1–4 Paraneoplastic cerebellar degeneration
(PCD) is one of the most common of these syndromes,
observed in individuals with gynecologic or breast cancer.
These patients usually have Yo antibodies in serum and
CSF.5–7 Evidence suggests that anti-Yo targets 2 intracellular
antigens, cerebellar degeneration-related protein 2 (CDR2)
and CDR2-like (CDR2L), expressed in the nucleus and
cytoplasm of Purkinje neurons in the cerebellum,
respectively.8–10 The interaction between anti-Yo and CDR
proteins is believed to mediate Purkinje neuron dysfunction
and death, leaving the patients in a severely disabled
state.11,12
Onconeural antibodies identified in the sera or CSF of pa-
tients are key diagnostic biomarkers for PCD.3 Commercial
line assays are available, but the diagnostic value of these tests
has been questioned.1,13 The specificity of anti-Yo is low, with
less than 10% confirmation rate.1 Because anti-Yo is associ-
ated with most PCD cases related to gynecologic and breast
cancer, improved diagnostic tests for anti-Yo is important to
ensure a correct clinical diagnosis and prevent unnecessary
tests or inappropriate treatment.
Our recent studies have suggested that CDR2L, which shares
50% sequence homology with CDR2, is likely the main target
of anti-Yo.12 We postulate that the low specificity for
detecting Yo antibodies seen with commercial immunoassays
is that they use CDR2 as the Yo-antigen. Here, we assessed
the value of including CDR2L as a diagnostic marker to in-
crease the specificity for Yo antibody detection.
Methods
Patients
We performed a retrospective analysis of 9,527 sera and CSF
samples from patients screened for onconeural antibodies at
the Neurological Research Laboratory, Haukeland University
Hospital, Bergen, from 2017 to 2020. We included the 24
patients with serum and/or CSF Yo reactive bands detected
by the commercial PNS 14 Line Assay from Ravo Diagnostika
(Freiburg im Breisgau, Germany) in the study. Positive
samples were also tested with EUROLINE PNS 12 Ag and
cell-based assay (CBA) fromEuroimmun (Lübeck, Germany)
and were further explored by indirect immunofluorescence of
rat cerebellar section. Samples were also tested in 2 assays for
CDR2L developed in-house.
Standard Protocol Approvals, Registration, and
Patient Consents
Patient records for the 24 included cases were obtained and
anonymized before the study. PCD was diagnosed according
to the established criteria.2 The study was approved by The
Regional Committee for Health and Medical Research Ethics
in Norway, REK #123524.
Commercial Line Immunoassays for
Anti-CDR2 Detection
The PNS 14 Line Assay (Ravo Diagnostika, #PNS14-003)
includes 14 different antigens for PNS: GAD65, HuD, Yo, Ri,
CV2/CRMP5, amphiphysin, Ma1, Ma2, SOX1, Tr/DNER,
Zic4, titin, recoverin, and Protein Kinase C γ. The EURO-
LINE PNS 12 Ag (Euroimmun, #DL1111-1601-7-G) in-
cludes 12 different antigens for PNS: amphiphysin, CV2/
CRMP5, Ma2, Ri, Yo, Hu, recoverin, SOX1, titin, Zic4,
GAD65, and Tr/DNER. Serum and CSF samples from 24
patients were analyzed in both immunoassays following the
manufacturer’s instructions. Two independent investigators
graded band intensities from + to +++, compared to a positive
control sample (+++).
The serum and CSF from the 24 patients were also tested for
anti-Yo using a commercial CBA (Purkinje Cell Mosaic 1;
Euroimmun, #FA1113-1005-1) consisting of BIOCHIP Mo-
saics with 4 positions (Yo/CDR2-, Tr/DNER-, ITPR1-, and
CARP-transfected human embryonic kidney 293 [HEK293]
cells), positive and negative controls. Briefly, aliquots of 30 μL
serum (diluted 1:100) or of CSF (diluted 1:1) were applied to
each reaction field on the BIOCHIP slide. After incubation
(30 minutes, room temperature), the slide was washed with
phosphate-buffered saline containing 0.2% Tween 20 (PBS-
Tween 20; 5 minutes, room temperature), followed by in-
cubation with goat anti-human IgG secondary antibody
conjugated to Alexa Fluor 488 (Thermo Fisher Scientific,
Waltham, MA, 1:500, #A-11013, 30 minutes, room temper-
ature). The slide was rinsed with PBS-Tween 20 andmounted
on a glass coverslip. The cutoff for Yo/CDR2was set to 1:100,
as advised by the manufacturer. Two independent investiga-
tors evaluated the results.
Indirect Immunofluorescence
All procedures were performed according to the NIH
Guidelines for the Care and Use of Laboratory Animals
Norway (FOTS 20135149/20157494/20170001). Wistar
Hannover GLAST rats were anesthetized and transcardially
perfused with ice-cold 4% paraformaldehyde (PFA) in PBS.
The brains were postfixed (24 hours, 4°C), incubated with
18% sucrose in PBS (72 hours, 4°C), snap-frozen, and cut on
Glossary
BSA = bovine serum albumin; CBA = cell-based assay; CDR2 = cerebellar degeneration-related protein 2; CDR2L = cerebellar
degeneration-related protein 2-like;HEK293 = human embryonic kidney 293; PCD = paraneoplastic cerebellar degeneration;
PFA = paraformaldehyde; PNS = paraneoplastic neurologic syndromes; SDS = sodium dodecyl sulfate.
2 Neurology: Neuroimmunology & Neuroinflammation | Volume 8, Number 2 | March 2021 Neurology.org/NN
a cryostat to 10-μm parasagittal sections.14 Heat-induced an-
tigen retrieval was performed with a pressure cooker in Diva
Decloaker buffer solution (Biocare Medical, Pacheco, CA;
#DV2004MX). Sections were blocked in bovine serum albu-
min (BSA) and Triton X-100 in PBS (2 hours, room temper-
ature), followed by incubation with patient samples (1:500 in
blocking solution, overnight, 4°C). Finally, the sections were
rinsed with PBS, incubated with secondary antibody (Alexa
Fluor 488 goat anti-human IgG, 1:100, 90 minutes, room
temperature), rinsed, and mounted with ProLong Diamond
Antifade Mountant with 4’,6-diamidino-2-phenylindole
(DAPI) (Thermo Fisher Scientific, #P36962).8
CBA for Anti-CDR2L Detection
HEK293 cells were cultured in 8-well Nunc Lab-Tec II Chamber
Slide System (Thermo Fisher Scientific, #154534) in Eagle
MinimumEssentialMedium supplementedwith 10% fetal bovine
serum and penicillin/streptomycin (37°C, 5% CO2). Cells were
transfected with a plasmid for expression of Myc-DDK-tagged
CDR2L (Origene, Rockville, MD; #RC206909) using Lipofect-
amine 3000 Reagent (Invitrogen, Carlsbad, CA; #L3000008).
At 48 hours after transfection, coverslips were washed with PBS
and fixed with 4% PFA/4% glucose in PBS (20 minutes, room
temperature). Demembranation with 0.1% triton X-100 in PBS
(7 minutes, room temperature) was followed by blocking with
Table Results of Commercial Line Immunoassays, Confirmatory Tests, Clinical Presentation, and Potential Cancer Found
in 24 Patients Tested for Anti-Yo
Patient F/M Age Ravoa EUROLINEa CBA CDR2 IIF CBA CDR2L WB (CDR2L/CDR2) Clinical presentation Cancer
1 F 37 Yo +++ Yo +++ + + + +/+ PCD Breast
2 F 63 Yo +++ Yo +++ + + + +/+ PCD Uterine
3 F 63 Yo +++ Yo +++ + + + +/+ PCD Uterine
4 F 74 Yo +++ Yo +++ + + + +/+ PCD Ovary
5b F 77 Yo +++ Yo +++ + + + +/+ PCD Uterine
6 F 73 Yo +++ Yo +++ + + + +/+ PCD Ovary
7c F 66 Yo +++ Yo +++ + + − +/+ Headache Breast
8 M 61 Yo ++ — + + − −/+ Polyneuropathy Lung
9 F 20 Yo ++ Yo ++ + − − −/+ Myalgia No
10 F 34 Yo + Yo ++ + − − −/+ Myalgia No
11 M 53 Yo ++ Yo +++ + − − −/+ Polyneuropathy No
12 M 47 Yo ++ Yo +++ + − − −/+ Confusion No
13 M 36 Yo + Yo ++ + − − −/+ Psychosis No
14 F 70 Yo ++ Yo ++ − − − −/+ Neuropathy No
15 M 47 Yo + Yo + − − − −/− Epilepsy No
16 M 71 Yo ++ Yo ++ − − − −/+ Neuropathy No
17 F 54 Yo + Yo ++ − − − −/− Myalgia No
18 F 69 Yo + − − − − −/− Encephalopathy No
19 M 35 Yo + Yo + − − − −/− Encephalopathy No
20 F 73 Yo + − − − − −/− Encephalopathy No
21 M 31 Yo + Yo ++ − − − −/− Psychosis No
22 M 74 Yo + − − − − −/− Myalgia No
23 F 42 Yo + Yo + − − − −/− Paresthesia No
24 M 71 Yo + Yo + − − − −/− Diplopia No
Abbreviations: CBA = cell-based assay; CDR2 = cerebellar degeneration-related protein 2; CDR2L = cerebellar degeneration-related protein 2-like; IIF = indirect
immunofluorescence; PCD = paraneoplastic cerebellar degeneration; WB = Western blot analysis.
a Lineblots were graded by trained investigators as − (negative), + (weak positive), ++ (moderate positive), or +++ (strong positive) depending on the band
intensity.
b All samples are sera except from patient 5, which was the CSF.
c All cancers were detected within 2 years of sampling except for patient 7 where cancer was diagnosed 19 years previously.
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10% Sea Block blocking buffer (Thermo Fisher Scientific,
#37527) in PBS (1 hour, room temperature). Coverslips were
incubated with the serum (1:10 and 1:100) or CSF (1:10 and
1:100), mouse anti-DYKDDDDK tag or FLAG tag (DDK)
(Origene, #TA50011-100, 1:1,000), anti-CDR2L (Protein
Technology, Pencroft Way, Manchester, UK; #14563-1-AP),
or anti-CDR2 (Sigma-Aldrich, St. Louis, MO; #HPA023870)
in blocking solution (1 hour, room temperature). Finally,
coverslips were washed with PBS, incubated with secondary
antibody (Alexa Fluor 488 goat anti-human, Alexa Fluor 488
goat anti-rabbit, or Alexa Fluor 594 goat-anti-mouse, Thermo
Fisher Scientific, #A-11013, #A-11008, #A-11005, respectively,
1 hour, room temperature) and mounted using ProLong Di-
amond Antifade Mountant with DAPI.
Western Blot for Anti-CDR2 and
Anti-CDR2L Detection
The transcription/translation-coupled reticulocyte lysate sys-
tem (Promega, Madison, WI; #L4610) was used for cell-free
protein expression of CDR2L and CDR2. Purified plasmids
encoding the 2 proteins (2.0 μg; Origene, RC204900 [CDR2]
and #RC206909 [CDR2L]) were incubated with the tran-
scription/translation lysate, T7 RNA polymerase promoter,
reaction buffer, recombinant RNasin ribonuclease inhibitor
(Promega, #N2511), and amino acid mixture (30°C, 1.5
hours). A negative control without plasmid was included in
each experiment. The reaction products were evaluated by
sodium dodecyl sulfate (SDS)-polyacrylamide gel electropho-
resis, followed by Western blot analysis.
The reticulocyte extract was denatured in Laemmli buffer (Bio-
Rad, Hercules, CA; #1610747, 95°C, 5 minutes) and 2.5%
β-mercaptoethanol subjected to SDS-polyacrylamide gel electro-
phoresis separation on a 10%TGX gel (Bio-Rad, #456-1035) and
transferred to a polyvinylidene difluoride membrane using the
Trans-Blot Turbo Transfer kit (Bio-Rad, #170-4274). The blots
were blocked in 5%drymilk (Bio-Rad, #170-6404) dissolved in 1x
Tris-buffered saline with 0.1% Tween 20 (TBS-Tween 20) and
incubated with serum or CSF sample diluted in 3% BSA in TBS-
Tween 20 (1:250/1:100, 4°C, overnight). Antibody fixation was
visualized using horseradish peroxidase anti-human IgG (Dako,
Carpinteria, CA; #P0214, 1 hour, room temperature).
Imaging
Rat cerebellar sections and CBAs were imaged on a Leica
Leitz DM RBE fluorescence microscope with CoolLED pE-
300-W LED illumination. Images were evaluated by 2 in-
dependent investigators. ImageJ was used for background
subtraction of microscopy images and evaluation of Western
blot results.
Data Availability
Data related to the current article are available from the cor-
responding authors on reasonable request.
Results
Between 2017 and 2020, 24 of 9,527 tested serum or CSF
samples (0.25%) from patients with suspected PNS showed a
reactive band for Yo antibodies using the PNS 14 Line Assay
from Ravo Diagnostika and 20 (83%) showed a reactive band
using EUROLINE PNS 12 Ag from Euroimmun (table).
Thirteen of the 24 patients (54%) had a confirmed positive
CBA CDR2 assay, whereas only 8 stained Purkinje cells in the
immunofluorescence assay (table).
Using staining of rat cerebellar sections as a confirmatory test,
we found that Yo positive sera from 6 PCD patients showed
granular, cytoplasmic staining in Purkinje neurons (figure
1A). In the group of 18 nonconfirmed PCD cases, serum
samples from 2 patients (7 and 8) stained Purkinje neurons
but with no granular cytoplasmic staining; these patients were
therefore interpreted as anti-Yo negative (figure 1B). The
remaining 16 serum samples were negative (figure 1C). The
commercial line immunoassays alone yielded a high number
of false positive results (18/24 [75%] for the Ravo assay and
16/24 [67%] for the Euroimmun assay). Even when com-
bined with the CBA CDR2 (Euroimmun), the false positive
rate was high at 7 of 24 (29%). The best-established method
for Yo antibody confirmation was careful interpretation of
Figure 1 Representative Images of Rat Cerebellar Sections Incubated With Patient Samples
(A) Sera from confirmed paraneoplastic cerebellar degeneration (PCD) cases (cerebellar degeneration-related protein 2-like [CDR2L]+/cerebellar de-
generation-related protein 2 [CDR2]+, patients 1–6) show granular, cytoplasmic staining of Purkinje neurons. (B) Sera from the 2 cases without PCD but with
previously detected cancer (CDR2L−/CDR2+, patients 7 and 8) stain the cytoplasm of Purkinje neurons, but no granular staining is observed. (C) Sera from the
remaining cases without PCD andwithout cancer (CDR2L−/CDR2+, patient 9–13) do not stain Purkinje neurons of rat cerebellar sections. CDR2L/CDR2 testing
is based on line blots and cell-based assays. G = granular layer; M =molecular layer; P = Purkinje neuron layer. Scale bar = 20 μm; zoom in scale bar = 10 μm.
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immunofluorescent staining of Purkinje neurons in rat cere-
bellar sections.
Because we recently showed that the major target for Yo-
antibodies is not CDR2, but CDR2L,12 we developed an assay
based on HEK293 cells transfected with a plasmid for ex-
pression of Myc-DDK-tagged CDR2L and stained these cells
with patient sera or CSF. To evaluate the specificity of our in-
house CDR2L CBA, HEK293 cells that express Myc-DDK-
tagged CDR2L were stained with anti-DDK, anti-CDR2L, or
anti-CDR2 (figure 2). There was complete overlap between
CDR2L and DDK cytoplasmic staining. The absence of
CDR2 antibody staining confirmed that there was no cross-
reactivity between CDR2 and CDR2L antibodies.
Samples from the 6 confirmed PCD cases stained both
CDR2L-transfected cells and commercial CBA for CDR2
(figure 3, A.a and A.b). However, the samples from the 7
patients with CBA CDR2-positive staining, but no PCD, did
not show CBA staining for CDR2L (figure 3, B.a and B.b).
These results were confirmed by Western blot analysis of
recombinant CDR2 (62 kDa) and CDR2L (55 kDa) proteins
(figure 3, A.c and B.c) with the exception of the sample from
one patient without PCD (patient7) who tested positive for
CDR2L in Western blot but not in CBA. We also found that
Western blot analysis with CDR2 was negative for 9 and 6
patients who were weak-to-moderate positive on the Ravo
and Euroimmun assays, respectively (table).
Discussion
Commercial line immunoassays enable simple and rapid de-
tection of onconeural antibodies in patients with suspected
PNS. In this study, we evaluated the diagnostic accuracy of Yo
antibody testing by commercial line immunoassays and rou-
tine confirmatory tests. We found an approximate 70% false
positivity rate using commercial assays alone, which is in line
with recent studies.1,13 The discrepancy between the 2 com-
mercial assays is most likely related to the nature of the an-
tigens: Both use recombinant CDR2 proteins, but the
sequence length, and therefore protein structure, and the cell
lines in which the recombinant CDR2 is produced differ.
Band intensities were graded from + to +++ compared to a
positive control. Overall, we observed that samples with in-
tense reactive bands on the line immunoassays were more
likely to be from patients with PCD than those with weaker
reactive bands, as was also reported recently.13
The number of false positive tests for PCD was reduced by
combining the results from the 2 line immunoassays with a
CBA for CDR2. In agreement with another study,1 we found
several men among the CDR2-positive but PCD-negative
patients, supporting the hypothesis that CDR2 is not the
natural Yo antigen.
In our hands, the best confirmatory test among the estab-
lished techniques were rat cerebellar immunofluorescence.
Figure 2NoCross-Reactivity Is Observed Between CDR2 Antibodies and CDR2L in Human Embryonic Kidney 293 Cells That
Express Myc-DDK-Tagged CDR2L
Upper row: cells stained with anti-CDR2L (green) and anti-DDK (red). Lower row: cells stained with anti-CDR2 (no reaction), and anti-DDK (red). Nuclei are
stained with DAPI. Scale bar = 20 μm. CDR2 = cerebellar degeneration-related protein 2; CDR2L = cerebellar degeneration-related protein 2-like.
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However, many clinical laboratories are not equipped to
perform indirect immunofluorescence assays, and Purkinje
cell staining can be difficult to interpret because only granular
cytoplasmic staining is characteristic of anti-Yo.8,12 This pat-
tern probably represents ribosomal staining because it has
been shown recently that CDR2L interacts with the ribosomal
subunit protein rpS6.10 Sera from 2 of our patients without
PCD, but with previous cancer, also stained the rat Purkinje
cell cytoplasm, but the cytoplasmic staining was not granular.
The specific target for this staining is unknown, but such false
positive anti-Yo staining must be interpreted with caution
because it is unrelated to PCD.
In our cohort of 24 patients, all positive for Yo antibodies
based on the commercial line immunoassays, only 6 had PCD.
This means that routine testing using only line immunoassays
must be performed with care and must be confirmed to pre-
vent misdiagnosis, unnecessary testing, and incorrect treat-
ment. Some laboratories use immunohistochemistry for initial
screening, which may avoid false positive results based on
commercial line immunoassays alone. However, these analy-
ses are laborious and require skilled personnel to interpret the
binding patterns.
We have previously shown that Yo antibodies bind both en-
dogenous and recombinant CDR2L but only recombinant
CDR2.12 These findings imply that there are independent
antibody responses to CDR2L and CDR2, supported by the
fact that the most highly enriched regions of CDR2L are the
most divergent regions between the 2 proteins.15 Because
CDR2 and CDR2L share common epitopes, this probably
explains the frequent detection of false positive results, which
are CDR2 restricted. This is supported by our recent findings
that PCD-related Yo antibodies bind only endogenous
CDR2L not endogenous CDR2.12
We hypothesized that the specificity of the routine commer-
cial tests could be increased by including CDR2L as a target
protein. In the present study, we developed 2 techniques for
detection of CDR2L: a CBA consisting of HEK293 cells that
express Myc-DDK-tagged CDR2L and a Western blot–based
analysis of recombinant CDR2 and CDR2L proteins. Our
CDR2L CBA identified all 6 patients with PCD and was
negative for the 18 nonconfirmed cases. Western blot analysis
with recombinant CDR2L identified the 6 PCD patients and
one patient with no PCD but with a previous diagnosis of
breast cancer. The apparent mismatch between our CBA and
Western blot assays is unclear but may represent a differently
expressed epitope of CDR2L detected by each of the 2 assays.
Interestingly, patients with weak-to-moderate positive com-
mercial line immunoassays were also found negative by the
CDR2 Western blot analysis, again suggesting differences in
the epitopes detected.
Although our study cohort is small, our data demonstrate
that detection of CDR2L adds an important dimension to
the diagnostic accuracy of PCD testing. Currently, we do
not know whether testing for CDR2L antibodies alone
would be sufficient for diagnosis of PCD because our co-
hort were selected based on anti-CDR2 positivity. This
question will require larger patient cohorts including
PCD patients who test negative in commercial line
Figure 3 Representative Images of Patient Sera (1:100) Double Positive for CDR2L and CDR2 (A.a–A.c), and Single Positive
for CDR2 (B.a–B.c) in Indirect Immunofluorescence of CDR2L Transfected Human Embryonic Kidney 293 Cells
(A.a, B.a), Commercial CBA for CDR2 (A.b, B.b), and WB (A.c, B.c)
A negative control containing reticulocyte lysate without recombinant protein was included in each experiment. Anti-CDR2/CDR2L, green; anti-DDK, red;
merge, yellow. Scale bar = 20 μm. CBA = cell-based assay; CDR2 = cerebellar degeneration-related protein 2; CDR2L = cerebellar degeneration-related protein
2-like; WB = Western blot analysis.
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immunoassays and patients who have PNS caused by other
onconeural antibodies.
In conclusion, our results underline the importance of confir-
matory tests when interpreting results from the currently com-
mercially available anti-Yo detection assays. The high proportion
of false positive results appears to be due to the use of CDR2 as
antigen. Therefore, all positive samples tested by commercial line
immunoassays must be confirmed by immunofluorescence or
immunohistochemistry. However, our results support the thesis
that CDR2L is the major Yo antigen, and we suggest that
CDR2L should be included in the commercially available line
immunoassays and CBAs for Yo antibody detection.
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